|
|
| G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
increases expression multiple interactions
|
ISO EXP
|
Cycloheximide results in increased expression of ABCB1 mRNA Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA] Cycloheximide inhibits the reaction [[Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [[Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; Cycloheximide inhibits the reaction [tetrabromobisphenol A results in increased expression of and results in increased activity of ABCB1A protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein]
|
CTD |
PMID:7476894 PMID:18474546 PMID:30830211 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
| G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ABCB4 mRNA]
|
CTD |
PMID:11331069 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
| G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions increases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in increased expression of ABCC3 mRNA Cycloheximide results in increased expression of ABCC3 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
| G
|
Abcc5
|
ATP binding cassette subfamily C member 5
|
multiple interactions decreases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in decreased expression of ABCC5 mRNA Cycloheximide results in decreased expression of ABCC5 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655
|
|
| G
|
Acsl3
|
acyl-CoA synthetase long-chain family member 3
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ACSL3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097
|
|
| G
|
Acsl6
|
acyl-CoA synthetase long-chain family member 6
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of ACSL6 mRNA]
|
CTD |
PMID:10585473 |
|
NCBI chr10:38,940,668...38,999,515
Ensembl chr10:38,940,747...39,002,873
|
|
| G
|
Adam17
|
ADAM metallopeptidase domain 17
|
decreases stability multiple interactions
|
ISO
|
Cycloheximide results in decreased stability of ADAM17 protein cordycepin inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]; N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]
|
CTD |
PMID:36558177 |
|
NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344
|
|
| G
|
Adam9
|
ADAM metallopeptidase domain 9
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of ADAM9 protein]
|
CTD |
PMID:17018608 |
|
NCBI chr16:73,725,186...73,804,284
Ensembl chr16:73,725,114...73,804,646
|
|
| G
|
Adm
|
adrenomedullin
|
multiple interactions increases expression
|
ISO
|
Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of ADM mRNA] Cycloheximide results in increased expression of ADM mRNA
|
CTD |
PMID:11032871 |
|
NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371
|
|
| G
|
Adora2b
|
adenosine A2B receptor
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ADORA2B mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091
|
|
| G
|
Adrb2
|
adrenoceptor beta 2
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of ADRB2 mRNA; Cycloheximide results in increased expression of ADRB2 protein [Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA; Cycloheximide inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; N(6)-benzoyl-cyclic AMP promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]
|
CTD |
PMID:22483689 PMID:24705868 |
|
NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803
|
|
| G
|
Ago3
|
argonaute RISC catalytic component 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA]
|
CTD |
PMID:29576526 |
|
NCBI chr 5:143,913,957...143,998,746
Ensembl chr 5:143,926,501...143,998,737
|
|
| G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions decreases expression increases localization
|
ISO
|
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein] Cycloheximide results in increased localization of AHR protein [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Tretinoin co-treated with Cycloheximide] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]
|
CTD |
PMID:9145908 PMID:10777561 PMID:12002481 PMID:12147270 PMID:15385644 PMID:16226227 PMID:20570689 PMID:21807577 More...
|
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
| G
|
Akap5
|
A-kinase anchoring protein 5
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP5 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620
|
|
| G
|
Akap6
|
A-kinase anchoring protein 6
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP6 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 6:75,919,350...76,359,667
Ensembl chr 6:75,919,513...76,355,036
|
|
| G
|
Akr1c3
|
aldo-keto reductase family 1, member C3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein]
|
CTD |
PMID:21787718 |
|
NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438
|
|
| G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions increases phosphorylation
|
EXP ISO
|
Cycloheximide inhibits the reaction [[Hydrogen Peroxide co-treated with sodium arsenite] results in increased phosphorylation of AKT1 protein] Cycloheximide results in increased phosphorylation of AKT1 protein
|
CTD |
PMID:12472888 PMID:28634229 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
| G
|
Aldh1a3
|
aldehyde dehydrogenase 1 family, member A3
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH1A3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777
|
|
| G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
multiple interactions affects expression
|
EXP ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ALDH3A1 mRNA; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of ALDH3A1 mRNA] Cycloheximide affects the expression of ALDH3A1 mRNA
|
CTD |
PMID:1953764 PMID:39580082 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
| G
|
Aldh3a2
|
aldehyde dehydrogenase 3 family, member A2
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH3A2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:46,427,789...46,448,449
Ensembl chr10:46,407,993...46,448,648
|
|
| G
|
Alox5ap
|
arachidonate 5-lipoxygenase activating protein
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ALOX5AP mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr12:10,785,254...10,809,295
Ensembl chr12:10,785,257...10,817,038
|
|
| G
|
Alpi
|
alkaline phosphatase, intestinal
|
decreases activity multiple interactions
|
ISO EXP
|
Cycloheximide results in decreased activity of ALPI protein Cycloheximide inhibits the reaction [Fish Oils results in increased activity of ALPI protein]
|
CTD |
PMID:15599000 PMID:20362602 |
|
NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780
|
|
| G
|
Amhr2
|
anti-Mullerian hormone receptor type 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AMHR2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 7:135,454,517...135,470,183
Ensembl chr 7:135,457,922...135,471,104
|
|
| G
|
Ank2
|
ankyrin 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ANK2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:218,052,555...218,537,259
|
|
| G
|
Ankrd27
|
ankyrin repeat domain 27
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ANKRD27 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:97,387,997...97,440,501
Ensembl chr 1:97,388,099...97,440,501
|
|
| G
|
Aoc1
|
amine oxidase, copper containing 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased activity of AOC1 protein]
|
CTD |
PMID:2860926 PMID:6218830 |
|
NCBI chr 4:79,143,126...79,162,705
Ensembl chr 4:79,143,126...79,162,704
|
|
| G
|
Apaf1
|
apoptotic peptidase activating factor 1
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of APAF1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of APAF1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772
|
|
| G
|
Aqp1
|
aquaporin 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of AQP1 mRNA]
|
CTD |
PMID:22415096 |
|
NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504
|
|
| G
|
Aqp4
|
aquaporin 4
|
multiple interactions
|
EXP
|
[Lactic Acid co-treated with Cycloheximide] results in increased expression of AQP4 protein
|
CTD |
PMID:18406487 |
|
NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098
|
|
| G
|
Areg
|
amphiregulin
|
multiple interactions increases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in increased expression of AREG mRNA Cycloheximide results in increased expression of AREG mRNA
|
CTD |
PMID:15072547 PMID:15228094 |
|
NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641
|
|
| G
|
Armc5
|
armadillo repeat containing 5
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ARMC5 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:192,250,580...192,257,347
Ensembl chr 1:192,249,939...192,257,348
|
|
| G
|
Arnt
|
aryl hydrocarbon receptor nuclear translocator
|
multiple interactions
|
ISO
|
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]
|
CTD |
PMID:12002481 PMID:20570689 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546
|
|
| G
|
Asb1
|
ankyrin repeat and SOCS box-containing 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ASB1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 9:99,566,852...99,588,321
Ensembl chr 9:99,567,867...99,583,907
|
|
| G
|
Asns
|
asparagine synthetase (glutamine-hydrolyzing)
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Methotrexate results in increased activity of ASNS protein]
|
CTD |
PMID:6122150 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050
|
|
| G
|
Atf3
|
activating transcription factor 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein]
|
CTD |
PMID:23593480 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750
|
|
| G
|
Atf4
|
activating transcription factor 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein] Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein]
|
CTD |
PMID:18533110 PMID:23593480 PMID:24057571 |
|
NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739
|
|
| G
|
Atg13
|
autophagy related 13
|
decreases expression
|
ISO
|
Cycloheximide results in decreased expression of ATG13 protein
|
CTD |
PMID:27629431 |
|
NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743
|
|
| G
|
Atp7a
|
ATPase copper transporting alpha
|
multiple interactions decreases expression
|
EXP
|
cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein]
|
CTD |
PMID:23174565 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093
|
|
| G
|
Avpr1a
|
arginine vasopressin receptor 1A
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AVPR1A mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:59,999,738...60,003,837
|
|
| G
|
Bach1
|
BTB domain and CNC homolog 1
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of BACH1 protein tetrachlorobenzoquinone promotes the reaction [Cycloheximide results in decreased expression of BACH1 protein]
|
CTD |
PMID:27393035 |
|
NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277
|
|
| G
|
Bap1
|
BRCA1 associated deubiquitinase 1
|
multiple interactions
|
ISO
|
BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]
|
CTD |
PMID:37414201 |
|
NCBI chr16:6,453,126...6,461,952
Ensembl chr16:6,452,974...6,461,952
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]
|
CTD |
PMID:9790906 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bbox1
|
gamma-butyrobetaine hydroxylase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BBOX1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 3:117,277,226...117,326,383
Ensembl chr 3:117,277,226...117,326,064
|
|
| G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]
|
CTD |
PMID:11726273 PMID:22343715 PMID:34303041 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
| G
|
Bcl2l1
|
Bcl2-like 1
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of BCL2L1 protein alternative form Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein]
|
CTD |
PMID:9326359 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
| G
|
Bcl2l14
|
Bcl2-like 14
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of BCL2L14 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:168,948,919...168,989,450
Ensembl chr 4:168,948,946...168,990,079
|
|
| G
|
Bdh1
|
3-hydroxybutyrate dehydrogenase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BDH1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636
|
|
| G
|
Becn1
|
beclin 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of BECN1 protein]
|
CTD |
PMID:16882451 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
| G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of BGLAP mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of BGLAP mRNA]
|
CTD |
PMID:17203194 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
| G
|
Bid
|
BH3 interacting domain death agonist
|
multiple interactions
|
ISO
|
[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; Cycloheximide inhibits the reaction [vorinostat results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]
|
CTD |
PMID:11535817 PMID:12925536 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275
|
|
| G
|
Bnip3
|
BCL2 interacting protein 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]
|
CTD |
PMID:19442826 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962
|
|
| G
|
Brca1
|
BRCA1, DNA repair associated
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA] BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]; Cycloheximide inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA]
|
CTD |
PMID:10344722 PMID:29576526 PMID:37414201 |
|
NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763
|
|
| G
|
Brca2
|
BRCA2, DNA repair associated
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA]
|
CTD |
PMID:10344722 |
|
NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194
|
|
| G
|
Calb1
|
calbindin 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CALB1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160
|
|
| G
|
Camlg
|
calcium modulating ligand
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CAMLG mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr17:8,997,868...9,009,140
Ensembl chr17:8,997,272...9,009,012
|
|
| G
|
Casp1
|
caspase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CASP1 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of CASP1 protein modified form]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP1 mRNA]
|
CTD |
PMID:11007951 PMID:26901245 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
| G
|
Casp3
|
caspase 3
|
multiple interactions increases activity
|
ISO EXP
|
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein] obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]
|
CTD |
PMID:12760867 PMID:12925536 PMID:14502240 PMID:15537749 PMID:15685448 PMID:15860571 PMID:17295206 PMID:18222423 PMID:18636177 PMID:22343715 PMID:34303041 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp4
|
caspase 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP4 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727
|
|
| G
|
Casp7
|
caspase 7
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of CASP7 mRNA]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]
|
CTD |
PMID:12760867 PMID:16166294 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
| G
|
Casp8
|
caspase 8
|
multiple interactions increases activity
|
ISO
|
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein] Cycloheximide results in increased activity of CASP8 protein
|
CTD |
PMID:12760867 PMID:12925536 PMID:15924153 PMID:18222423 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
| G
|
Casp9
|
caspase 9
|
multiple interactions increases activity
|
ISO
|
[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein] Cycloheximide results in increased activity of CASP9 protein
|
CTD |
PMID:12925536 PMID:14502240 PMID:18222423 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
| G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of CAT protein]; Cycloheximide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CAT protein]
|
CTD |
PMID:6845354 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Catsper4
|
cation channel, sperm associated 4
|
affects response to substance
|
ISO
|
CATSPER4 gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr 5:151,711,415...151,731,083
Ensembl chr 5:151,711,194...151,730,750
|
|
| G
|
Cav1
|
caveolin 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of CAV1 mRNA]
|
CTD |
PMID:15314095 |
|
NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740
|
|
| G
|
Cbl
|
Cbl proto-oncogene
|
multiple interactions
|
ISO
|
CBL protein affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]
|
CTD |
PMID:39880321 |
|
NCBI chr 8:53,384,656...53,468,067
Ensembl chr 8:53,384,656...53,468,067
|
|
| G
|
Cbx1
|
chromobox 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CBX1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:82,266,746...82,286,431
Ensembl chr10:82,266,759...82,287,242
|
|
| G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions increases expression
|
ISO
|
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]
|
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
| G
|
Ccl5
|
C-C motif chemokine ligand 5
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of CCL5 mRNA Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]
|
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884
|
|
| G
|
Ccn1
|
cellular communication network factor 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Acetylcysteine results in increased expression of CCN1 protein]
|
CTD |
PMID:21055460 |
|
NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883
|
|
| G
|
Ccn2
|
cellular communication network factor 2
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of CCN2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
| G
|
Ccn3
|
cellular communication network factor 3
|
multiple interactions increases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in decreased expression of CCN3 mRNA Cycloheximide results in increased expression of CCN3 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581
|
|
| G
|
Ccn4
|
cellular communication network factor 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased expression of CCN4 mRNA]
|
CTD |
PMID:19238344 |
|
NCBI chr 7:100,534,578...100,566,287
Ensembl chr 7:100,534,505...100,563,094
|
|
| G
|
Ccna2
|
cyclin A2
|
multiple interactions decreases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in increased expression of CCNA2 mRNA Cycloheximide results in decreased expression of CCNA2 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701
|
|
| G
|
Ccnd1
|
cyclin D1
|
multiple interactions decreases expression
|
ISO EXP
|
[gingerol co-treated with Cycloheximide] results in increased degradation of CCND1 protein; Cycloheximide inhibits the reaction [CXCL8 protein results in increased expression of CCND1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]] Cycloheximide results in decreased expression of CCND1 mRNA
|
CTD |
PMID:17606477 PMID:18058799 PMID:25923732 PMID:27853917 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
| G
|
Ccnd3
|
cyclin D3
|
affects expression multiple interactions
|
ISO
|
Cycloheximide affects the expression of CCND3 mRNA Cycloheximide affects the reaction [Estradiol affects the expression of CCND3 mRNA]
|
CTD |
PMID:9094091 |
|
NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033
|
|
| G
|
Cct5
|
chaperonin containing TCP1 subunit 5
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCT5 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:84,302,623...84,313,779
|
|
| G
|
Cd38
|
CD38 molecule
|
multiple interactions
|
ISO
|
Cycloheximide affects the reaction [Tretinoin results in increased expression of CD38 mRNA]
|
CTD |
PMID:21393419 |
|
NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505
|
|
| G
|
Cd3e
|
CD3 epsilon subunit of T-cell receptor complex
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD3E mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876
|
|
| G
|
Cd44
|
CD44 molecule
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of CD44 protein]
|
CTD |
PMID:9929743 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424
|
|
| G
|
Cd47
|
Cd47 molecule
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD47 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr11:64,374,816...64,438,763
Ensembl chr11:64,377,926...64,438,272
|
|
| G
|
Cd63
|
Cd63 molecule
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD63 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 7:1,909,538...1,924,937
Ensembl chr 7:1,922,169...1,924,938
|
|
| G
|
Cd8a
|
CD8 subunit alpha
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CD8A mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:104,924,116...104,928,353
Ensembl chr 4:104,900,833...104,928,358
|
|
| G
|
Cdc42se2
|
CDC42 small effector 2
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of CDC42SE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CDC42SE2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:39,337,269...39,405,772
Ensembl chr 1:100,424,547...100,424,801 Ensembl chr10:100,424,547...100,424,801
|
|
| G
|
Cdca5
|
cell division cycle associated 5
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of CDCA5 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CDCA5 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:212,807,863...212,821,313
Ensembl chr 1:212,804,014...212,821,309
|
|
| G
|
Cdca7l
|
cell division cycle associated 7 like
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of CDCA7L protein]
|
CTD |
PMID:31285264 |
|
NCBI chr 6:144,936,885...144,982,844
Ensembl chr 6:144,908,171...144,982,843
|
|
| G
|
Cdh1
|
cadherin 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Cycloheximide promotes the reaction [necrostatin-1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]]
|
CTD |
PMID:39461407 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
| G
|
Cdk2
|
cyclin dependent kinase 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA]
|
CTD |
PMID:12800980 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
| G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions decreases expression
|
ISO EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of CDKN1A mRNA]; Cycloheximide inhibits the reaction [Troglitazone results in increased expression of CDKN1A protein]; Furazolidone promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein] Cycloheximide results in decreased expression of CDKN1A mRNA; Cycloheximide results in decreased expression of CDKN1A protein Cycloheximide inhibits the reaction [manganese chloride results in increased expression of CDKN1A protein] Cycloheximide promotes the reaction [Dexamethasone results in decreased expression of CDKN1A protein]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CDKN1A mRNA]
|
CTD |
PMID:10441511 PMID:12690110 PMID:22542671 PMID:24211769 PMID:26687534 PMID:28424418 PMID:28940008 PMID:31645432 More...
|
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
| G
|
Cdkn2a
|
cyclin-dependent kinase inhibitor 2A
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of CDKN2A mRNA
|
CTD |
PMID:17257637 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248
|
|
| G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of CFLAR protein; Cycloheximide results in decreased expression of CFLAR protein alternative form; Cycloheximide results in decreased expression of CFLAR protein modified form shogaol promotes the reaction [Cycloheximide results in decreased expression of CFLAR protein modified form]
|
CTD |
PMID:12663669 PMID:15924153 PMID:16077199 PMID:16951203 PMID:25619640 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
| G
|
Cftr
|
CF transmembrane conductance regulator
|
affects expression
|
EXP
|
Cycloheximide affects the expression of CFTR mRNA
|
CTD |
PMID:17290305 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
| G
|
Chrm1
|
cholinergic receptor, muscarinic 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Dihydrotestosterone results in decreased expression of CHRM1 mRNA]
|
CTD |
PMID:17624924 |
|
NCBI chr 1:214,996,180...215,012,136
Ensembl chr 1:214,995,872...215,020,602
|
|
| G
|
Cish
|
cytokine inducible SH2-containing protein
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of CISH mRNA
|
CTD |
PMID:23237828 |
|
NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986
|
|
| G
|
Cited2
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CITED2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782
|
|
| G
|
Ckb
|
creatine kinase B
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Estradiol results in increased expression of CKB protein]; Cycloheximide inhibits the reaction [Methoxychlor results in increased expression of CKB protein]
|
CTD |
PMID:7839363 |
|
NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478
|
|
| G
|
Clcn3
|
chloride voltage-gated channel 3
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CLCN3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr16:34,138,004...34,210,984
Ensembl chr16:34,137,952...34,210,984
|
|
| G
|
Cnr1
|
cannabinoid receptor 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]] Cycloheximide results in decreased expression of and affects the localization of CNR1 protein
|
CTD |
PMID:17041005 PMID:22258905 PMID:27513693 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252
|
|
| G
|
Col10a1
|
collagen type X alpha 1 chain
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of COL10A1 mRNA]
|
CTD |
PMID:16350840 |
|
NCBI chr20:39,737,536...39,744,518
Ensembl chr20:39,716,822...39,751,440
|
|
| G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:15962303 PMID:17203194 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
| G
|
Creb1
|
cAMP responsive element binding protein 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA]
|
CTD |
PMID:29576526 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
| G
|
Crppa
|
CDP-L-ribitol pyrophosphorylase A
|
affects response to substance
|
ISO
|
CRPPA gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr 6:58,847,550...59,124,309
Ensembl chr 6:58,848,621...59,181,406
|
|
| G
|
Cryl1
|
crystallin, lambda 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CRYL1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr15:35,542,628...35,661,563
Ensembl chr15:35,542,628...35,661,563
|
|
| G
|
Csf1
|
colony stimulating factor 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc results in increased expression of CSF1 mRNA]
|
CTD |
PMID:12112025 PMID:17295206 PMID:18636177 |
|
NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468
|
|
| G
|
Csf2
|
colony stimulating factor 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein]
|
CTD |
PMID:9606035 PMID:10645887 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
| G
|
Csnk1d
|
casein kinase 1, delta
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr10:106,713,497...106,754,953
Ensembl chr10:106,694,279...106,754,953
|
|
| G
|
Csnk2b
|
casein kinase 2 beta
|
multiple interactions decreases degradation
|
ISO
|
Diethylhexyl Phthalate inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]; TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]
|
CTD |
PMID:37302538 |
|
NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525
|
|
| G
|
Ctnnb1
|
catenin beta 1
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of CTNNB1 protein CBL protein affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]; Phenobarbital affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]; Tetrachlorodibenzodioxin promotes the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]
|
CTD |
PMID:27693619 PMID:39880321 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
| G
|
Ctsb
|
cathepsin B
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Azithromycin results in increased activity of CTSB protein]
|
CTD |
PMID:8830663 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478
|
|
| G
|
Cul2
|
cullin 2
|
multiple interactions
|
ISO
|
CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]
|
CTD |
PMID:31645432 |
|
NCBI chr17:58,864,274...58,905,447
Ensembl chr17:58,864,274...58,905,132
|
|
| G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]
|
CTD |
PMID:22121136 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261
|
|
| G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CYCS mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
| G
|
Cyp11a1
|
cytochrome P450, family 11, subfamily a, polypeptide 1
|
decreases expression
|
EXP
|
Cycloheximide results in decreased expression of CYP11A1 protein
|
CTD |
PMID:21126571 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196
|
|
| G
|
Cyp19a1
|
cytochrome P450, family 19, subfamily a, polypeptide 1
|
decreases activity decreases expression
|
ISO EXP
|
Cycloheximide results in decreased activity of CYP19A1 protein Cycloheximide results in decreased expression of CYP19A1 protein
|
CTD |
PMID:16480277 PMID:21126571 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917
|
|
| G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
affects expression increases expression multiple interactions
|
EXP ISO
|
Cycloheximide affects the expression of CYP1A1 mRNA Cycloheximide results in increased expression of CYP1A1 mRNA 3'-methoxy-4'-nitroflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; [Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; beta-Naphthoflavone promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Tetrachlorodibenzodioxin affects the expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide promotes the reaction [[Benzo(a)pyrene co-treated with Calcitriol] results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Skatole results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Tetrachlorodibenzodioxin affects the reaction [Cycloheximide affects the expression of CYP1A1 mRNA] [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Piperonyl Butoxide co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dactinomycin promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
|
CTD |
PMID:1321828 PMID:1849469 PMID:1934297 PMID:2985607 PMID:8647108 PMID:9102211 PMID:9145908 PMID:9233375 PMID:10777561 PMID:11007951 PMID:11516172 PMID:11710520 PMID:12002481 PMID:12111005 PMID:15371557 PMID:15385644 PMID:16093525 PMID:17599377 PMID:17606337 PMID:19244278 PMID:19684285 PMID:20187624 PMID:20570689 PMID:22037238 PMID:28424418 PMID:29524502 PMID:39580082 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
| G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]
|
CTD |
PMID:1849469 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
| G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
increases expression multiple interactions affects expression
|
ISO EXP
|
Cycloheximide results in increased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1B1 mRNA; Cycloheximide affects the reaction [Tetrachlorodibenzodioxin affects the expression of CYP1B1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Tetrachlorodibenzodioxin affects the reaction [Cycloheximide affects the expression of CYP1B1 mRNA] Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of CYP1B1 protein]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Cycloheximide results in increased expression of CYP1B1 mRNA]
|
CTD |
PMID:9145908 PMID:19684285 PMID:21867498 PMID:39580082 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
| G
|
Cyp24a1
|
cytochrome P450, family 24, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
alpha-naphthoflavone inhibits the reaction [Cycloheximide promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]]; Cycloheximide inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]
|
CTD |
PMID:19244278 |
|
NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083
|
|
| G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions increases degradation
|
ISO EXP
|
(4-amidinophenyl)methanesulfonyl fluoride inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; acetonitrile inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Carbon Tetrachloride promotes the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Cycloheximide promotes the reaction [Carbon Tetrachloride results in increased degradation of CYP2E1 protein]; Dimethyl Sulfoxide inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Edetic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Egtazic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Ethanol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; fomepizole inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Glycerol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; leupeptin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] Cycloheximide inhibits the reaction [pyridine results in increased activity of CYP2E1 protein]; Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP2E1 protein]
|
CTD |
PMID:1968335 PMID:8531136 PMID:9143349 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
| G
|
Cyp2f4
|
cytochrome P450, family 2, subfamily f, polypeptide 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]
|
CTD |
PMID:20187624 |
|
NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553
|
|
| G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions decreases expression
|
EXP ISO
|
Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A2 mRNA] Cycloheximide results in decreased expression of CYP3A4 mRNA
|
CTD |
PMID:11181506 PMID:21466820 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
| G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A23-3A1 mRNA]
|
CTD |
PMID:11181506 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
| G
|
Dag1
|
dystroglycan 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DAG1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 8:117,769,517...117,834,347
Ensembl chr 8:117,769,517...117,782,199
|
|
| G
|
Dcn
|
decorin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DCN mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926
|
|
| G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [plumbagin results in increased expression of DDIT3 protein]
|
CTD |
PMID:31276663 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
| G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
increases expression multiple interactions
|
EXP
|
Cycloheximide results in increased expression of DDIT4 protein [EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein
|
CTD |
PMID:22689575 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037
|
|
| G
|
Deaf1
|
DEAF1 transcription factor
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DEAF1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:205,831,428...205,865,106
Ensembl chr 1:205,831,336...205,865,106
|
|
| G
|
Degs1
|
delta(4)-desaturase, sphingolipid 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DEGS1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302
|
|
| G
|
Dio2
|
iodothyronine deiodinase 2
|
multiple interactions decreases activity
|
ISO
|
[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]; lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]
|
CTD |
PMID:11425850 PMID:26004626 |
|
NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594
|
|
| G
|
Dio3
|
iodothyronine deiodinase 3
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein]
|
CTD |
PMID:18420745 |
|
NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985
|
|
| G
|
Dnajb5
|
DnaJ heat shock protein family (Hsp40) member B5
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DNAJB5 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 5:61,972,637...61,981,887
Ensembl chr 5:61,972,706...61,981,860
|
|
| G
|
Dnase1l3
|
deoxyribonuclease 1L3
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of DNASE1L3 protein
|
CTD |
PMID:15118903 |
|
NCBI chr15:19,351,683...19,378,536
Ensembl chr15:19,352,493...19,378,531
|
|
| G
|
Dnm1l
|
dynamin 1-like
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of DNM1L mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DNM1L mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420
|
|
| G
|
Dnmt3a
|
DNA methyltransferase 3 alpha
|
multiple interactions
|
EXP
|
[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein
|
CTD |
PMID:19833194 |
|
NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970
|
|
| G
|
Edn1
|
endothelin 1
|
multiple interactions
|
ISO
|
[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA
|
CTD |
PMID:22483689 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
| G
|
Ednra
|
endothelin receptor type A
|
multiple interactions
|
EXP
|
[Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA mRNA; [Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA protein; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein]
|
CTD |
PMID:20561571 |
|
NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284
|
|
| G
|
Ednrb
|
endothelin receptor type B
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]
|
CTD |
PMID:20561571 PMID:20716444 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
| G
|
Egf
|
epidermal growth factor
|
multiple interactions
|
EXP
|
[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]
|
CTD |
PMID:12632255 PMID:22689575 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
| G
|
Egfr
|
epidermal growth factor receptor
|
increases expression multiple interactions
|
ISO EXP
|
Cycloheximide results in increased expression of EGFR mRNA Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein]
|
CTD |
PMID:15228094 PMID:26368632 PMID:30237564 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
| G
|
Egr1
|
early growth response 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]
|
CTD |
PMID:12690110 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
| G
|
Egr2
|
early growth response 2
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of EGR2 mRNA
|
CTD |
PMID:19350554 |
|
NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748
|
|
| G
|
Eif2a
|
eukaryotic translation initiation factor 2A
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [epimedokoreanin B results in increased phosphorylation of EIF2A protein]; Cycloheximide inhibits the reaction [Orlistat results in increased phosphorylation of EIF2A protein]
|
CTD |
PMID:17283163 PMID:36027945 |
|
NCBI chr 2:144,911,247...144,944,705
Ensembl chr 2:144,911,153...144,945,201
|
|
| G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
multiple interactions
|
EXP ISO
|
Cycloheximide inhibits the reaction [dimethylarsinous acid results in increased phosphorylation of EIF2AK3 protein] Cycloheximide inhibits the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [1,12-benzoperylene results in increased expression of EIF2AK3 mRNA]]
|
CTD |
PMID:22425709 PMID:35182551 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
| G
|
Eif2s1
|
eukaryotic translation initiation factor 2 subunit alpha
|
increases expression multiple interactions increases phosphorylation
|
ISO
|
Cycloheximide results in increased expression of EIF2S1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of EIF2S1 mRNA Cycloheximide results in increased phosphorylation of EIF2S1 protein
|
CTD |
PMID:19684285 PMID:24315374 |
|
NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649
|
|
| G
|
Eif4e
|
eukaryotic translation initiation factor 4E
|
multiple interactions
|
ISO EXP
|
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]] Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]
|
CTD |
PMID:22689575 PMID:25923732 |
|
NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105
|
|
| G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]; Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein]
|
CTD |
PMID:22689575 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
| G
|
Eif4g1
|
eukaryotic translation initiation factor 4 gamma 1
|
multiple interactions
|
EXP
|
Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein]
|
CTD |
PMID:22689575 |
|
NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367
|
|
| G
|
Eif4g3
|
eukaryotic translation initiation factor 4 gamma, 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of EIF4G3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:155,481,378...155,702,194
|
|
| G
|
Eif5
|
eukaryotic translation initiation factor 5
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of EIF5 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 6:136,410,333...136,418,827
Ensembl chr 6:136,407,440...136,418,821
|
|
| G
|
Elavl1
|
ELAV like RNA binding protein 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]
|
CTD |
PMID:25923732 |
|
NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631
|
|
| G
|
Elf4
|
E74 like ETS transcription factor 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELF4 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr X:132,465,290...132,508,175
Ensembl chr X:132,468,539...132,478,689
|
|
| G
|
Elk1
|
ETS transcription factor ELK1
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of ELK1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ELK1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249
|
|
| G
|
Eln
|
elastin
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Okadaic Acid results in decreased expression of ELN mRNA]
|
CTD |
PMID:8997264 |
|
NCBI chr12:27,604,983...27,648,413
Ensembl chr12:27,604,680...27,648,413
|
|
| G
|
Elovl3
|
ELOVL fatty acid elongase 3
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of ELOVL3 mRNA Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of ELOVL3 mRNA]
|
CTD |
PMID:17726147 |
|
NCBI chr 1:254,938,731...254,942,559
Ensembl chr 1:254,938,731...254,942,559
|
|
| G
|
Enc1
|
ectodermal-neural cortex 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of ENC1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721
|
|
| G
|
Endog
|
endonuclease G
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ENDOG mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573
|
|
| G
|
Epas1
|
endothelial PAS domain protein 1
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]; MALAT1 mRNA inhibits the reaction [Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]] Cycloheximide results in decreased expression of EPAS1 protein
|
CTD |
PMID:23958427 PMID:26735578 |
|
NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729
|
|
| G
|
Epo
|
erythropoietin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
|
CTD |
PMID:10756076 |
|
NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725
|
|
| G
|
Epyc
|
epiphycan
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EPYC mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 7:34,323,332...34,360,845
Ensembl chr 7:34,323,273...34,361,032
|
|
| G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
multiple interactions decreases expression increases degradation
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA; Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]; PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] Cycloheximide results in decreased expression of ERBB2 mRNA; Cycloheximide results in decreased expression of ERBB2 protein
|
CTD |
PMID:15072547 PMID:15228094 PMID:20379846 PMID:25866362 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481
|
|
| G
|
Erbb3
|
erb-b2 receptor tyrosine kinase 3
|
decreases expression
|
ISO
|
Cycloheximide results in decreased expression of ERBB3 mRNA
|
CTD |
PMID:15228094 |
|
NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120
|
|
| G
|
Ereg
|
epiregulin
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of EREG mRNA
|
CTD |
PMID:15228094 |
|
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260
|
|
| G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of ERN1 protein]
|
CTD |
PMID:26784903 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791
|
|
| G
|
Esr1
|
estrogen receptor 1
|
multiple interactions decreases expression
|
ISO
|
bisphenol A promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; Estradiol promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein]
|
CTD |
PMID:24586459 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
| G
|
Esr2
|
estrogen receptor 2
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]]
|
CTD |
PMID:15207704 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709
|
|
| G
|
Esrra
|
estrogen related receptor, alpha
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of ESRRA protein HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein]
|
CTD |
PMID:34524571 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811
|
|
| G
|
Ext2
|
exostosin glycosyltransferase 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EXT2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 3:100,120,776...100,253,424
Ensembl chr 3:100,120,776...100,253,596
|
|
| G
|
F12
|
coagulation factor XII
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of F12 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr17:9,212,819...9,220,664
Ensembl chr17:9,212,819...9,220,664
|
|
| G
|
F2
|
coagulation factor II, thrombin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]
|
CTD |
PMID:14630613 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
| G
|
F3
|
coagulation factor III, tissue factor
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tretinoin results in decreased expression of F3 mRNA]
|
CTD |
PMID:11876987 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369
|
|
| G
|
Fas
|
Fas cell surface death receptor
|
multiple interactions increases response to substance
|
ISO
|
Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein] Cycloheximide results in increased susceptibility to FAS protein
|
CTD |
PMID:8932996 PMID:12760867 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
| G
|
Faslg
|
Fas ligand
|
multiple interactions
|
ISO EXP
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FASLG mRNA] [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein
|
CTD |
PMID:11007951 PMID:19833194 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
| G
|
Fasn
|
fatty acid synthase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Calcitriol results in decreased expression of FASN mRNA]
|
CTD |
PMID:12798352 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
| G
|
Fbl
|
fibrillarin
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FBL mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:92,597,407...92,606,507
Ensembl chr 1:92,597,258...92,606,506
|
|
| G
|
Fbxw7
|
F-box and WD repeat domain containing 7
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]
|
CTD |
PMID:24457827 PMID:25897075 |
|
NCBI chr 2:172,447,738...172,609,591
Ensembl chr 2:172,447,738...172,609,591
|
|
| G
|
Fga
|
fibrinogen alpha chain
|
decreases expression
|
EXP
|
Cycloheximide results in decreased expression of FGA protein
|
CTD |
PMID:444225 |
|
NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577
|
|
| G
|
Fgb
|
fibrinogen beta chain
|
decreases expression
|
EXP
|
Cycloheximide results in decreased expression of FGB protein
|
CTD |
PMID:444225 |
|
NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434
|
|
| G
|
Fgf2
|
fibroblast growth factor 2
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA]
|
CTD |
PMID:9798919 PMID:15654655 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493
|
|
| G
|
Fgfr1
|
Fibroblast growth factor receptor 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]
|
CTD |
PMID:12805413 |
|
NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855
|
|
| G
|
Fgl2
|
fibrinogen-like 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FGL2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 4:14,602,762...14,608,405
Ensembl chr 4:14,602,771...14,608,405
|
|
| G
|
Fhit
|
fragile histidine triad diadenosine triphosphatase
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FHIT mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr15:16,365,401...17,872,901
Ensembl chr15:16,747,338...17,872,621
|
|
| G
|
Fhl1
|
four and a half LIM domains 1
|
multiple interactions
|
EXP
|
Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]
|
CTD |
PMID:17161435 |
|
NCBI chr X:139,592,794...139,652,290
Ensembl chr X:139,592,604...139,652,282
|
|
| G
|
Flt3
|
Fms related receptor tyrosine kinase 3
|
decreases expression
|
ISO
|
Cycloheximide results in decreased expression of FLT3 protein mutant form
|
CTD |
PMID:32284743 |
|
NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581
|
|
| G
|
Fmo3
|
flavin containing dimethylaniline monoxygenase 3
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of FMO3 mRNA
|
CTD |
PMID:20570689 |
|
NCBI chr13:77,838,899...77,868,869
Ensembl chr13:77,842,602...77,861,256
|
|
| G
|
Fmr1
|
fragile X messenger ribonucleoprotein 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FMR1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr X:152,284,857...152,322,686
Ensembl chr X:152,284,841...152,322,675
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO EXP
|
Cycloheximide inhibits the reaction [Estradiol results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Genistein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of FOS protein]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA] Cycloheximide results in increased expression of FOS mRNA [Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA; Cadmium Chloride promotes the reaction [Cycloheximide results in increased expression of FOS mRNA]; Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of FOS protein]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA] Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]
|
CTD |
PMID:1696944 PMID:9094091 PMID:9417049 PMID:9650640 PMID:12632255 PMID:15090535 PMID:15136564 PMID:20495008 More...
|
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Frk
|
fyn-related Src family tyrosine kinase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FRK mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr20:39,820,441...39,926,065
Ensembl chr20:39,820,295...39,926,362
|
|
| G
|
Fst
|
follistatin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FST mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:47,856,345...47,863,491
|
|
| G
|
Fth1
|
ferritin heavy chain 1
|
multiple interactions decreases expression
|
ISO
|
[Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTH1 protein]
|
CTD |
PMID:39954839 |
|
NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214
|
|
| G
|
Ftl1
|
ferritin light chain 1
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of FTL protein [Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTL protein]
|
CTD |
PMID:39954839 |
|
NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915 Ensembl chr 2:45,399,355...45,399,915 Ensembl chr 1:45,399,355...45,399,915
|
|
| G
|
Fut4
|
fucosyltransferase 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FUT4 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436
|
|
| G
|
Fzd7
|
frizzled class receptor 7
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FZD7 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585
|
|
| G
|
G6pd
|
glucose-6-phosphate dehydrogenase
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of G6PD protein]
|
CTD |
PMID:1978808 |
|
NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144
|
|
| G
|
Galnt1
|
polypeptide N-acetylgalactosaminyltransferase 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GALNT1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588
|
|
| G
|
Gas1
|
growth arrest-specific 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GAS1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr17:4,487,716...4,490,701
Ensembl chr17:4,484,283...4,497,657
|
|
| G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
multiple interactions
|
ISO EXP
|
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLC mRNA]; Cycloheximide inhibits the reaction [diphenylarsinic acid results in increased expression of GCLC protein] Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]
|
CTD |
PMID:17628625 PMID:19328227 PMID:24437944 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
| G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLM mRNA]
|
CTD |
PMID:19328227 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
| G
|
Gdf15
|
growth differentiation factor 15
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA]; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein]; Cycloheximide inhibits the reaction [troglitazone results in increased expression of GDF15 mRNA]
|
CTD |
PMID:14662774 PMID:18801729 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022
|
|
| G
|
Gja1
|
gap junction protein, alpha 1
|
multiple interactions decreases expression
|
EXP
|
9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Cycloheximide results in decreased expression of GJA1 protein]; Cycloheximide promotes the reaction [Benzo(a)pyrene results in decreased expression of GJA1 protein]
|
CTD |
PMID:34283317 PMID:36863560 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
| G
|
Gpaa1
|
glycosylphosphatidylinositol anchor attachment 1
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of GPAA1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of GPAA1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 7:109,932,556...109,936,139
Ensembl chr 7:109,932,544...109,936,138
|
|
| G
|
Gpr37
|
G protein-coupled receptor 37
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GPR37 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 4:55,104,355...55,126,420
Ensembl chr 4:55,104,365...55,126,494
|
|
| G
|
Gpx4
|
glutathione peroxidase 4
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of GPX4 protein triptolide promotes the reaction [Cycloheximide results in decreased expression of GPX4 protein]
|
CTD |
PMID:38960301 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
| G
|
Grm5
|
glutamate metabotropic receptor 5
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA]; Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein]
|
CTD |
PMID:11665859 |
|
NCBI chr 1:150,722,711...151,297,585
Ensembl chr 1:150,733,678...151,296,649
|
|
| G
|
Grn
|
granulin precursor
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GRN mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,886,122...87,893,936
|
|
| G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GSK3B mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
| G
|
Gsta2
|
glutathione S-transferase alpha 2
|
multiple interactions decreases expression
|
ISO
|
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]]; Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA] Cycloheximide results in decreased expression of GSTA1 mRNA
|
CTD |
PMID:16243960 |
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092
|
|
| G
|
Hbegf
|
heparin-binding EGF-like growth factor
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of HBEGF mRNA
|
CTD |
PMID:15228094 |
|
NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220
|
|
| G
|
Hdac6
|
histone deacetylase 6
|
multiple interactions
|
ISO
|
HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein]
|
CTD |
PMID:34524571 |
|
NCBI chr X:17,222,538...17,244,373
Ensembl chr X:17,222,856...17,244,370
|
|
| G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
increases degradation multiple interactions decreases expression
|
ISO EXP
|
Cycloheximide results in increased degradation of HIF1A protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Polystyrenes analog results in increased expression of HIF1A protein] Cycloheximide results in decreased expression of HIF1A [Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with Oxygen deficiency] affects the expression of HIF1A protein; [Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein; Butyric Acid promotes the reaction [Cycloheximide results in decreased expression of HIF1A protein]; Cycloheximide affects the reaction [[Apigenin co-treated with Oxygen deficiency] affects the expression of HIF1A protein]; Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein]; Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of HIF1A protein]; Cycloheximide inhibits the reaction [zinc chloride results in increased expression of HIF1A protein alternative form]; Cycloheximide promotes the reaction [Cobalt results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [sodium arsenite inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; genipin affects the reaction [[Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose co-treated with Cycloheximide] results in decreased expression of HIF1A protein]; scutellarin promotes the reaction [Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; sodium arsenite inhibits the reaction [Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]] Cycloheximide promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein]
|
CTD |
PMID:11641398 PMID:11739637 PMID:19958256 PMID:20524035 PMID:22537771 PMID:23593480 PMID:24188932 PMID:24221993 PMID:24497960 PMID:25192544 PMID:27286880 PMID:29630948 PMID:30266538 PMID:31285264 PMID:31850806 PMID:34717917 PMID:34900531 PMID:35513012 PMID:36709824 PMID:39241941 More...
|
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions decreases expression
|
ISO EXP
|
Cycloheximide inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein] Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [puerarin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Triterpenes analog results in increased expression of HMOX1 protein] Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]
|
CTD |
PMID:9747510 PMID:12441344 PMID:12472888 PMID:15118350 PMID:15588712 PMID:15876423 PMID:15965080 PMID:16647178 PMID:17002867 PMID:18357586 PMID:19781563 PMID:20020468 PMID:20060010 PMID:20833156 PMID:21840424 PMID:24255720 PMID:24437944 PMID:25239868 PMID:26385185 PMID:30076913 PMID:35821281 PMID:39431643 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hnrnph2
|
heterogeneous nuclear ribonucleoprotein H2
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of HNRNPH2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr X:102,074,175...102,080,115
Ensembl chr X:102,074,179...102,081,025
|
|
| G
|
Hnrnpk
|
heterogeneous nuclear ribonucleoprotein K
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Glycine results in increased expression of HNRNPK protein]
|
CTD |
PMID:24990929 |
|
NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,268,385...6,280,565
|
|
| G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [tributyltin results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [triphenyltin chloride results in increased expression of HSD11B2 mRNA]
|
CTD |
PMID:31927052 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812
|
|
| G
|
Hsf1
|
heat shock transcription factor 1
|
decreases activity
|
ISO
|
Cycloheximide results in decreased activity of HSF1 protein
|
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
| G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
multiple interactions
|
EXP ISO
|
Cycloheximide inhibits the reaction [GIF 0010 results in increased expression of HSPA5 mRNA]; Cycloheximide inhibits the reaction [lead acetate results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Mercuric Chloride results in increased expression of HSPA5 protein] Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [plumbagin results in increased expression of HSPA5 protein]
|
CTD |
PMID:9742210 PMID:17915553 PMID:26784903 PMID:31276663 PMID:34560123 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
| G
|
Htatip2
|
HIV-1 Tat interactive protein 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of HTATIP2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815
|
|
| G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] Cycloheximide results in decreased expression of ICAM1 protein
|
CTD |
PMID:16087364 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
| G
|
Ier3
|
immediate early response 3
|
multiple interactions
|
ISO
|
[afimoxifene co-treated with Cycloheximide] results in increased expression of IER3 mRNA
|
CTD |
PMID:16849584 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
| G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
[Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein]
|
CTD |
PMID:12070711 PMID:16087364 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Ift27
|
intraflagellar transport 27
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IFT27 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 7:111,619,145...111,635,129
Ensembl chr 7:111,619,077...111,634,936
|
|
| G
|
Igf1
|
insulin-like growth factor 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [IGF1 protein affects the metabolism of 1,2-diacylglycerol] IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]
|
CTD |
PMID:2120207 PMID:26687534 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
| G
|
Igf2bp3
|
insulin-like growth factor 2 mRNA binding protein 3
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein]
|
CTD |
PMID:36822301 |
|
NCBI chr 4:79,391,367...79,525,923
Ensembl chr 4:79,393,067...79,525,730
|
|
| G
|
Igfbp4
|
insulin-like growth factor binding protein 4
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of IGFBP4 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473
|
|
| G
|
Il10
|
interleukin 10
|
multiple interactions increases expression decreases response to substance
|
ISO EXP
|
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA] Cycloheximide results in increased expression of IL10 mRNA IL10 protein results in decreased susceptibility to Cycloheximide
|
CTD |
PMID:19395591 PMID:22183712 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
| G
|
Il17a
|
interleukin 17A
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Glucose results in increased secretion of IL17A protein]
|
CTD |
PMID:18310510 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331
|
|
| G
|
Il18
|
interleukin 18
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]
|
CTD |
PMID:18660453 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
| G
|
Il1a
|
interleukin 1 alpha
|
multiple interactions increases expression
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1A mRNA Cycloheximide results in increased expression of IL1A mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
ISO EXP
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1B mRNA; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL1B protein]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of IL1B protein modified form] Cycloheximide results in increased expression of IL1B mRNA Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]
|
CTD |
PMID:8071060 PMID:9606035 PMID:11112151 PMID:11286988 PMID:19684285 PMID:26901245 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il5
|
interleukin 5
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of IL5 protein T0901317 inhibits the reaction [Cycloheximide results in decreased expression of IL5 protein]
|
CTD |
PMID:23150660 |
|
NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003
|
|
| G
|
Il6
|
interleukin 6
|
multiple interactions increases secretion increases expression decreases secretion
|
ISO
|
Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL6 protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] Cycloheximide results in decreased secretion of IL6 protein
|
CTD |
PMID:8071060 PMID:11216681 PMID:12185005 PMID:21146893 PMID:24771768 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
| G
|
Il6st
|
interleukin 6 cytokine family signal transducer
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL6ST mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182
|
|
| G
|
Ins1
|
insulin 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]
|
CTD |
PMID:19070612 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
| G
|
Ins2
|
insulin 2
|
multiple interactions
|
ISO
|
[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]
|
CTD |
PMID:22537771 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805
|
|
| G
|
Iqgap1
|
IQ motif containing GTPase activating protein 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IQGAP1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043
|
|
| G
|
Irs1
|
insulin receptor substrate 1
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of IRS1 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IRS1 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538
|
|
| G
|
Itgb3
|
integrin subunit beta 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800
|
|
| G
|
Itgb6
|
integrin subunit beta 6
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB6 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA]
|
CTD |
PMID:11007951 PMID:21303922 |
|
NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:65,456,713...65,530,333
|
|
| G
|
Itpk1
|
inositol-tetrakisphosphate 1-kinase
|
multiple interactions
|
ISO
|
ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]
|
CTD |
PMID:12925536 |
|
NCBI chr 6:127,475,589...127,609,320
Ensembl chr 6:127,476,808...127,609,062
|
|
| G
|
Itpr1
|
inositol 1,4,5-trisphosphate receptor, type 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Ethanol results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITPR1 mRNA]
|
CTD |
PMID:11007951 PMID:17241155 |
|
NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504
|
|
| G
|
Ivns1abp
|
influenza virus NS1A binding protein
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Doxorubicin results in decreased expression of IVNS1ABP mRNA]
|
CTD |
PMID:17016628 |
|
NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547
|
|
| G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
increases stability multiple interactions increases phosphorylation
|
EXP ISO
|
Cycloheximide results in increased stability of JUN protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein] Cycloheximide promotes the reaction [Cadmium results in increased expression of JUN mRNA] Cycloheximide results in increased phosphorylation of JUN protein
|
CTD |
PMID:1696944 PMID:9751194 PMID:12169099 PMID:23593480 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
| G
|
Kank1
|
KN motif and ankyrin repeat domains 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KANK1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:232,381,720...232,500,834
Ensembl chr 1:232,445,658...232,500,839
|
|
| G
|
Kiaa0930
|
KIAA0930 homolog
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KIAA0930 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 7:117,947,898...117,987,601
Ensembl chr 7:117,947,898...117,987,636
|
|
| G
|
Kng1
|
kininogen 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein]
|
CTD |
PMID:16696851 |
|
NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148
|
|
| G
|
Kras
|
KRAS proto-oncogene, GTPase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320
|
|
| G
|
Kremen1
|
kringle containing transmembrane protein 1
|
affects response to substance
|
ISO
|
KREMEN1 gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr14:84,295,931...84,361,534
Ensembl chr14:84,297,700...84,361,614
|
|
| G
|
Krt13
|
keratin 13
|
multiple interactions
|
ISO
|
[afimoxifene co-treated with Cycloheximide] results in increased expression of KRT13 mRNA
|
CTD |
PMID:16849584 |
|
NCBI chr10:85,552,287...85,556,499
Ensembl chr10:85,552,287...85,556,499
|
|
| G
|
Krtcap2
|
keratinocyte associated protein 2
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KRTCAP2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 2:176,952,167...176,956,163
Ensembl chr 2:176,949,809...176,956,163
|
|
| G
|
Lck
|
LCK proto-oncogene, Src family tyrosine kinase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267
|
|
| G
|
Ldlr
|
low density lipoprotein receptor
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [Quercetin results in increased expression of LDLR protein] Cycloheximide results in decreased expression of LDLR protein
|
CTD |
PMID:22388943 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675
|
|
| G
|
Lep
|
leptin
|
multiple interactions
|
ISO
|
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein]
|
CTD |
PMID:31199479 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
| G
|
Lepr
|
leptin receptor
|
multiple interactions decreases expression
|
ISO
|
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein]
|
CTD |
PMID:31199479 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215
|
|
| G
|
Lgals3
|
galectin 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of LGALS3 protein]
|
CTD |
PMID:21821001 |
|
NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737
|
|
| G
|
Lhb
|
luteinizing hormone subunit beta
|
multiple interactions
|
EXP
|
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA]
|
CTD |
PMID:11416027 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445
|
|
| G
|
Lmo7
|
LIM domain 7
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LMO7 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551
|
|
| G
|
Lpxn
|
leupaxin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LPXN mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 1:219,353,319...219,387,743
Ensembl chr 1:219,353,708...219,387,742
|
|
| G
|
Maf1
|
MAF1 homolog, negative regulator of RNA polymerase III
|
increases degradation multiple interactions
|
ISO
|
Cycloheximide results in increased degradation of MAF1 protein Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein]; CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]
|
CTD |
PMID:31645432 |
|
NCBI chr 7:109,955,876...109,958,909
Ensembl chr 7:109,955,282...109,958,910
|
|
| G
|
Map2k1
|
mitogen activated protein kinase kinase 1
|
multiple interactions increases activity
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA] Cycloheximide results in increased activity of MAP2K1 protein
|
CTD |
PMID:23237828 |
|
NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
ISO EXP
|
Cycloheximide results in increased phosphorylation of MAPK1 protein TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]] Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide promotes the reaction [[sodium arsenite co-treated with Hydrogen Peroxide] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of MAPK14 protein]
|
CTD |
PMID:17507666 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO EXP
|
Cycloheximide results in increased phosphorylation of MAPK3 protein TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]] Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide promotes the reaction [sodium arsenite promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]]
|
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mapk7
|
mitogen-activated protein kinase 7
|
multiple interactions increases expression
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MAPK7 mRNA; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK7 mRNA] Cycloheximide results in increased expression of MAPK7 mRNA
|
CTD |
PMID:11007951 PMID:19684285 |
|
NCBI chr10:46,669,721...46,675,768
Ensembl chr10:46,669,721...46,675,806
|
|
| G
|
Mapkapk3
|
MAPK activated protein kinase 3
|
affects response to substance
|
ISO
|
MAPKAPK3 gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr 8:116,808,429...116,842,228
Ensembl chr 8:116,808,429...116,842,228
|
|
| G
|
Mbp
|
myelin basic protein
|
affects expression
|
EXP
|
Cycloheximide affects the expression of MBP mRNA
|
CTD |
PMID:22954530 |
|
NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174
|
|
| G
|
Mcl1
|
MCL1 apoptosis regulator, BCL2 family member
|
multiple interactions decreases expression
|
ISO
|
[Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [Resveratrol co-treated with Clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]
|
CTD |
PMID:14982947 PMID:21880625 PMID:24924397 PMID:25408576 PMID:25923732 PMID:35561756 More...
|
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782
|
|
| G
|
Mdk
|
midkine
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MDK mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 3:98,356,789...98,358,960
Ensembl chr 3:98,356,789...98,358,743
|
|
| G
|
Mir21
|
microRNA 21
|
multiple interactions increases expression
|
ISO
|
Cycloheximide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [Estradiol results in decreased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA] Cycloheximide results in increased expression of MIR21 mRNA
|
CTD |
PMID:19264808 PMID:23052036 |
|
NCBI chr10:71,902,600...71,902,691
|
|
| G
|
Mitf
|
melanocyte inducing transcription factor
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein]; [Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein
|
CTD |
PMID:30849679 |
|
NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790
|
|
| G
|
Mmp1
|
matrix metallopeptidase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MMP1 mRNA]
|
CTD |
PMID:15075337 PMID:19136476 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
| G
|
Mmp13
|
matrix metallopeptidase 13
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of MMP13 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MMP13 mRNA Cycloheximide inhibits the reaction [Tretinoin results in increased expression of MMP13 mRNA]
|
CTD |
PMID:16350840 PMID:19684285 |
|
NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105
|
|
| G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of MMP2 mRNA]
|
CTD |
PMID:26621329 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
| G
|
Mnx1
|
motor neuron and pancreas homeobox 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MNX1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 4:6,541,645...6,546,604
Ensembl chr 4:6,541,645...6,546,604
|
|
| G
|
Mpg
|
N-methylpurine-DNA glycosylase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MPG mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr10:15,900,697...15,906,981
Ensembl chr10:15,899,635...15,907,052
|
|
| G
|
Mrps7
|
mitochondrial ribosomal protein S7
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of MRPS7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of MRPS7 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:101,342,642...101,345,790
Ensembl chr10:101,342,421...101,346,082
|
|
| G
|
Msh3
|
mutS homolog 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MSH3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 2:25,179,400...25,320,857
Ensembl chr 2:25,179,400...25,321,102
|
|
| G
|
Msr1
|
macrophage scavenger receptor 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA]
|
CTD |
PMID:9614211 |
|
NCBI chr16:59,421,250...59,507,070
Ensembl chr16:59,421,057...59,507,070
|
|
| G
|
Mt1a
|
metallothionein 1A
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of MT1 mRNA 2-tert-butylhydroquinone promotes the reaction [Cycloheximide results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]; MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA]
|
CTD |
PMID:14998373 PMID:19276070 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200 Ensembl chr X:79,695,809...79,696,200 Ensembl chr19:79,695,809...79,696,200
|
|
| G
|
Mtch2
|
mitochondrial carrier 2
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTCH2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 3:97,286,388...97,306,028
Ensembl chr 3:97,285,894...97,307,327
|
|
| G
|
Mterf3
|
mitochondrial transcription termination factor 3
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of MTERF3 protein Ammonium Chloride inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]
|
CTD |
PMID:35904214 |
|
NCBI chr 7:65,711,654...65,729,926
Ensembl chr 7:65,711,662...65,729,895
|
|
| G
|
Mtf1
|
metal-regulatory transcription factor 1
|
multiple interactions
|
ISO
|
MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA]
|
CTD |
PMID:19276070 |
|
NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810
|
|
| G
|
Mtmr7
|
myotubularin related protein 7
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of MTMR7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTMR7 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr16:58,344,755...58,435,682
Ensembl chr16:58,344,767...58,436,615
|
|
| G
|
Mxd1
|
max dimerization protein 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MXD1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 4:120,654,731...120,678,972
Ensembl chr 4:120,654,731...120,675,129
|
|
| G
|
Mxd3
|
Max dimerization protein 3
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MXD3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr17:9,306,552...9,310,278
Ensembl chr17:9,302,321...9,310,278
|
|
| G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions
|
ISO EXP
|
arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] Cycloheximide promotes the reaction [Cadmium results in increased expression of MYC mRNA] Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of MYC protein]
|
CTD |
PMID:1696944 PMID:23593480 PMID:24457827 PMID:31285264 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
| G
|
Mylk
|
myosin light chain kinase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]
|
CTD |
PMID:15701621 |
|
NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659
|
|
| G
|
Myo1d
|
myosin ID
|
affects response to substance
|
ISO
|
MYO1D gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958
|
|
| G
|
Nbr1
|
NBR1, autophagy cargo receptor
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of NBR1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NBR1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:86,978,024...87,006,664
Ensembl chr10:86,977,885...87,007,012
|
|
| G
|
Ndrg1
|
N-myc downstream regulated 1
|
multiple interactions decreases expression
|
ISO
|
Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of NDRG1 protein]
|
CTD |
PMID:28906492 |
|
NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913
|
|
| G
|
Nedd4
|
NEDD4 E3 ubiquitin protein ligase
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of NEDD4 protein Melatonin promotes the reaction [Cycloheximide results in decreased expression of NEDD4 protein]
|
CTD |
PMID:31325559 |
|
NCBI chr 8:82,264,751...82,349,642
Ensembl chr 8:82,264,649...82,349,633
|
|
| G
|
Nefh
|
neurofilament heavy chain
|
decreases expression decreases degradation
|
EXP
|
Cycloheximide results in decreased expression of NEFH mRNA Cycloheximide results in decreased degradation of NEFH mRNA
|
CTD |
PMID:1280263 PMID:19146868 |
|
NCBI chr14:84,044,428...84,054,413
Ensembl chr14:84,044,023...84,054,417
|
|
| G
|
Nefl
|
neurofilament light chain
|
decreases expression decreases degradation
|
EXP
|
Cycloheximide results in decreased expression of NEFL mRNA Cycloheximide results in decreased degradation of NEFL mRNA
|
CTD |
PMID:1280263 PMID:19146868 |
|
NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515
|
|
| G
|
Nefm
|
neurofilament medium chain
|
decreases degradation
|
EXP
|
Cycloheximide results in decreased degradation of NEFM mRNA
|
CTD |
PMID:1280263 |
|
NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163
|
|
| G
|
Nek2
|
NIMA-related kinase 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NEK2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr13:105,936,809...105,950,054
Ensembl chr13:105,936,788...105,950,056
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions decreases expression
|
ISO
|
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of NFE2L2 protein]; Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]; exenatide inhibits the reaction [Cycloheximide results in decreased expression of NFE2L2 protein] [SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; Curcumin inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]
|
CTD |
PMID:12441344 PMID:14510636 PMID:15322212 PMID:22019695 PMID:22197970 PMID:25896339 PMID:27286880 PMID:27939242 PMID:34758851 More...
|
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
affects localization increases expression multiple interactions
|
ISO
|
Cycloheximide affects the localization of NFKB1 protein Cycloheximide results in increased expression of NFKB1 mRNA Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]
|
CTD |
PMID:16637064 PMID:21146893 PMID:24457827 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions increases degradation decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKBIA mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NFKBIA protein]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in decreased expression of NFKBIA protein]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased degradation of NFKBIA protein]
|
CTD |
PMID:11007951 PMID:15330761 PMID:16637064 PMID:21692457 PMID:22258905 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
| G
|
Ngf
|
nerve growth factor
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]
|
CTD |
PMID:20495008 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834
|
|
| G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of NLRP3 protein]
|
CTD |
PMID:26901245 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [[Raloxifene Hydrochloride co-treated with 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid] results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS2 mRNA]
|
CTD |
PMID:10760090 PMID:11007951 PMID:28138957 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
| G
|
Npy1r
|
neuropeptide Y receptor Y1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387
|
|
| G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
decreases expression multiple interactions
|
ISO EXP
|
Cycloheximide results in decreased expression of NQO1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]]; Cycloheximide inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [arsenite results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Cadmium results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Chromium results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA] Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]
|
CTD |
PMID:14510636 PMID:16243960 PMID:18474416 PMID:24437944 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
| G
|
Nr0b1
|
nuclear receptor subfamily 0, group B, member 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NR0B1 mRNA]
|
CTD |
PMID:18787026 |
|
NCBI chr X:54,707,658...54,711,786
Ensembl chr X:54,707,639...54,712,083
|
|
| G
|
Nr1h3
|
nuclear receptor subfamily 1, group H, member 3
|
multiple interactions increases expression
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NR1H3 mRNA Cycloheximide results in increased expression of NR1H3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532
|
|
| G
|
Nr3c1
|
nuclear receptor subfamily 3, group C, member 1
|
multiple interactions
|
ISO EXP
|
Cycloheximide inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone binds to NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein] Cycloheximide promotes the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA]
|
CTD |
PMID:21569845 PMID:31778773 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843
|
|
| G
|
Nr4a1
|
nuclear receptor subfamily 4, group A, member 1
|
multiple interactions
|
EXP
|
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA]
|
CTD |
PMID:11416027 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041
|
|
| G
|
Nucks1
|
nuclear casein kinase and cyclin-dependent kinase substrate 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NUCKS1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr13:45,897,275...45,926,491
Ensembl chr13:45,897,248...45,923,101
|
|
| G
|
Odc1
|
ornithine decarboxylase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Paraquat results in increased activity of ODC1 protein]
|
CTD |
PMID:7662713 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146
|
|
| G
|
Opa1
|
OPA1, mitochondrial dynamin like GTPase
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of OPA1 protein alternative form]
|
CTD |
PMID:20678484 |
|
NCBI chr11:84,612,943...84,690,025
Ensembl chr11:84,615,340...84,689,955
|
|
| G
|
Oprk1
|
opioid receptor, kappa 1
|
multiple interactions increases expression
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of OPRK1 mRNA Cycloheximide results in increased expression of OPRK1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671
|
|
| G
|
Oprm1
|
opioid receptor, mu 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of OPRM1 mRNA]
|
CTD |
PMID:16434616 |
|
NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756
|
|
| G
|
Orm1
|
orosomucoid 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Dexamethasone results in increased expression of ORM1 mRNA]
|
CTD |
PMID:20599767 |
|
NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667
|
|
| G
|
Pa2g4
|
proliferation-associated 2G4
|
multiple interactions
|
ISO
|
PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein]
|
CTD |
PMID:20379846 |
|
NCBI chr 7:1,569,326...1,576,794
Ensembl chr 7:1,569,327...1,576,802
|
|
| G
|
Pappa
|
pappalysin 1
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of PAPPA mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PAPPA mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:83,513,358...83,751,361
|
|
| G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO EXP
|
[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein] Cycloheximide results in increased cleavage of PARP1 protein Cycloheximide inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein]
|
CTD |
PMID:12925536 PMID:15147502 PMID:16051428 PMID:18222423 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
| G
|
Pax3
|
paired box 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PAX3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141
|
|
| G
|
Pcgf1
|
polycomb group ring finger 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PCGF1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:117,140,144...117,144,729
Ensembl chr 4:117,142,061...117,145,040
|
|
| G
|
Pck1
|
phosphoenolpyruvate carboxykinase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of PCK1 mRNA]
|
CTD |
PMID:9518257 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561
|
|
| G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Vitamin K 3 results in decreased expression of PCNA protein]
|
CTD |
PMID:21533478 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
| G
|
Pdcd2
|
programmed cell death 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PDCD2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 1:65,158,034...65,163,524
Ensembl chr 1:65,158,034...65,163,524
|
|
| G
|
Penk
|
proenkephalin
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PENK mRNA]; Cycloheximide promotes the reaction [Colforsin results in increased expression of PENK mRNA]
|
CTD |
PMID:11113530 |
|
NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:21,981,382...21,986,705
|
|
| G
|
Pi4ka
|
phosphatidylinositol 4-kinase alpha
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PI4KA mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr11:97,113,390...97,234,374
Ensembl chr11:97,113,245...97,228,315
|
|
| G
|
Pigh
|
phosphatidylinositol glycan anchor biosynthesis, class H
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGH mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 6:103,601,369...103,630,214
Ensembl chr 6:103,601,520...103,630,159
|
|
| G
|
Pigk
|
phosphatidylinositol glycan anchor biosynthesis, class K
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGK mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 2:244,289,928...244,375,394
Ensembl chr 2:244,250,621...244,376,030
|
|
| G
|
Pik3c3
|
phosphatidylinositol 3-kinase, catalytic subunit type 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3C3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr18:22,119,677...22,203,546
Ensembl chr18:22,119,792...22,203,539
|
|
| G
|
Pik3cg
|
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3CG mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509
|
|
| G
|
Pilrb1
|
paired immunoglobin-like type 2 receptor beta 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PILRB mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr12:24,220,304...24,239,811
|
|
| G
|
Pla2g1b
|
phospholipase A2 group IB
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G1B mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr12:46,802,932...46,814,511
Ensembl chr12:46,802,939...46,813,693
|
|
| G
|
Pla2g4a
|
phospholipase A2 group 4A
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Dexamethasone inhibits the reaction [Zymosan results in increased activity of PLA2G4A protein]]
|
CTD |
PMID:10874129 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641
|
|
| G
|
Plat
|
plasminogen activator, tissue type
|
multiple interactions
|
EXP
|
Cycloheximide promotes the reaction [Isoproterenol results in increased expression of PLAT mRNA]
|
CTD |
PMID:2477232 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696
|
|
| G
|
Plaur
|
plasminogen activator, urokinase receptor
|
multiple interactions increases expression
|
ISO
|
[Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA; [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA Cycloheximide results in increased expression of PLAUR mRNA
|
CTD |
PMID:12070711 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130
|
|
| G
|
Pld3
|
phospholipase D family, member 3
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of PLD3 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:91,949,465...91,971,834
Ensembl chr 1:91,949,467...91,961,207
|
|
| G
|
Pln
|
phospholamban
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PLN mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241
|
|
| G
|
Plp1
|
proteolipid protein 1
|
multiple interactions increases expression
|
EXP
|
Cycloheximide promotes the reaction [Tretinoin results in increased expression of PLP1 mRNA] Cycloheximide results in increased expression of PLP1 mRNA
|
CTD |
PMID:19450544 |
|
NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314
|
|
| G
|
Pmaip1
|
phorbol-12-myristate-13-acetate-induced protein 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Fenretinide results in increased expression of PMAIP1 protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PMAIP1 protein]
|
CTD |
PMID:17216584 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382
|
|
| G
|
Pml
|
PML nuclear body scaffold
|
decreases degradation multiple interactions
|
ISO
|
Cycloheximide results in decreased degradation of PML protein modified form Cycloheximide inhibits the reaction [arsenic trioxide results in increased degradation of PML protein]
|
CTD |
PMID:20943951 PMID:26049103 |
|
NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083
|
|
| G
|
Pnpla2
|
patatin-like phospholipase domain containing 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PNPLA2 protein]
|
CTD |
PMID:18643838 |
|
NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359
|
|
| G
|
Pnpla6
|
patatin-like phospholipase domain containing 6
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein]
|
CTD |
PMID:20380879 |
|
NCBI chr12:6,372,284...6,401,632
Ensembl chr12:6,372,293...6,401,631
|
|
| G
|
Pomc
|
proopiomelanocortin
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [POMC protein modified form results in increased chemical synthesis of Adrenal Cortex Hormones]
|
CTD |
PMID:2993719 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173
|
|
| G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions decreases expression
|
ISO
|
POR protein mutant form promotes the reaction [Cycloheximide results in decreased expression of POR protein]
|
CTD |
PMID:27496950 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
| G
|
Pou5f1
|
POU class 5 homeobox 1
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [Cobalt results in increased expression of POU5F1 protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of POU5F1 protein]
|
CTD |
PMID:24497960 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598
|
|
| G
|
Ppan
|
peter pan homolog
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPAN mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 8:27,700,147...27,704,127
Ensembl chr 8:27,700,152...27,704,128
|
|
| G
|
Ppp1r15a
|
protein phosphatase 1, regulatory subunit 15A
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of PPP1R15A protein arsenite inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; Cycloheximide affects the reaction [arsenite results in increased expression of PPP1R15A protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PPP1R15A protein]
|
CTD |
PMID:29109149 |
|
NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774
|
|
| G
|
Ppp3cb
|
protein phosphatase 3 catalytic subunit beta
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPP3CB mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr15:3,809,182...3,854,204
Ensembl chr15:3,809,262...3,854,203
|
|
| G
|
Ppp4r3b
|
protein phosphatase 4, regulatory subunit 3B
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPP4R3B mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr14:107,118,116...107,166,121
Ensembl chr14:107,118,131...107,166,134
|
|
| G
|
Prdx4
|
peroxiredoxin 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRDX4 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr X:43,876,374...43,893,815
Ensembl chr X:43,876,417...43,893,812
|
|
| G
|
Prkcb
|
protein kinase C, beta
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of PRKCB mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PRKCB mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740
|
|
| G
|
Prkcd
|
protein kinase C, delta
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCD protein]
|
CTD |
PMID:11118818 |
|
NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839
|
|
| G
|
Prkce
|
protein kinase C, epsilon
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCE protein]
|
CTD |
PMID:11118818 |
|
NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288
|
|
| G
|
Prkcz
|
protein kinase C, zeta
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRKCZ mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674
|
|
| G
|
Psen1
|
presenilin 1
|
multiple interactions
|
ISO
|
[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]
|
CTD |
PMID:22302987 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189
|
|
| G
|
Psen2
|
presenilin 2
|
multiple interactions
|
ISO
|
Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]
|
CTD |
PMID:22302987 |
|
NCBI chr13:94,499,451...94,528,419
Ensembl chr13:94,499,928...94,525,116
|
|
| G
|
Psmd1
|
proteasome 26S subunit, non-ATPase 1
|
multiple interactions
|
ISO
|
PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]
|
CTD |
PMID:31645432 |
|
NCBI chr 9:94,157,971...94,233,218
Ensembl chr 9:94,157,971...94,233,218
|
|
| G
|
Psme3
|
proteasome activator subunit 3
|
multiple interactions
|
ISO
|
PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein]
|
CTD |
PMID:31645432 |
|
NCBI chr10:86,757,933...86,765,719
Ensembl chr10:86,757,899...86,818,033
|
|
| G
|
Pten
|
phosphatase and tensin homolog
|
multiple interactions
|
ISO
|
Cycloheximide affects the reaction [sodium arsenite affects the expression of PTEN protein]; Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; Cycloheximide inhibits the reaction [Rosiglitazone results in increased expression of PTEN protein]
|
CTD |
PMID:16425225 PMID:33256086 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
| G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions increases expression affects expression
|
ISO EXP
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of PTGS2 mRNA; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein]; Cycloheximide inhibits the reaction [Tretinoin results in increased expression of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] Cycloheximide results in increased expression of PTGS2 mRNA Cycloheximide affects the expression of PTGS2 mRNA
|
CTD |
PMID:7575673 PMID:11112151 PMID:11286988 PMID:16696851 PMID:16894348 PMID:22767315 PMID:39580082 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
| G
|
Ptn
|
pleiotrophin
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of PTN mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTN mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:66,260,764...66,342,614
Ensembl chr 4:66,260,764...66,342,482
|
|
| G
|
Ptp4a1
|
protein tyrosine phosphatase 4A1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Cycloheximide promotes the reaction [Estradiol results in increased expression of PTP4A1 mRNA]
|
CTD |
PMID:19146866 |
|
NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:40,710,250...40,718,176
|
|
| G
|
Ptp4a3
|
protein tyrosine phosphatase 4A3
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTP4A3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 7:107,518,220...107,549,949
Ensembl chr 7:107,541,047...107,549,949
|
|
| G
|
Ptpn5
|
protein tyrosine phosphatase, non-receptor type 5
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein]
|
CTD |
PMID:17623046 |
|
NCBI chr 1:106,756,896...106,817,369
Ensembl chr 1:106,756,896...106,816,828
|
|
| G
|
Rabepk
|
Rab9 effector protein with kelch motifs
|
affects response to substance
|
ISO
|
RABEPK gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr 3:38,460,205...38,481,077
Ensembl chr 3:38,460,206...38,480,688
|
|
| G
|
Rapgef1
|
Rap guanine nucleotide exchange factor 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RAPGEF1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 3:33,296,211...33,414,119
Ensembl chr 3:33,296,230...33,414,119
|
|
| G
|
Rarb
|
retinoic acid receptor, beta
|
multiple interactions increases expression
|
EXP
|
Cycloheximide promotes the reaction [Tretinoin results in increased expression of RARB mRNA] Cycloheximide results in increased expression of RARB mRNA
|
CTD |
PMID:19450544 |
|
NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040
|
|
| G
|
Rarres2
|
retinoic acid receptor responder 2
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of RARRES2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RARRES2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457
|
|
| G
|
Rb1
|
RB transcriptional corepressor 1
|
multiple interactions
|
ISO
|
RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]
|
CTD |
PMID:20100483 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857
|
|
| G
|
Rbl1
|
RB transcriptional corepressor like 1
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RBL1 mRNA]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]
|
CTD |
PMID:11007951 PMID:20100483 |
|
NCBI chr 3:166,226,187...166,289,862
Ensembl chr 3:166,226,198...166,289,376
|
|
| G
|
Rbpj
|
recombination signal binding protein for immunoglobulin kappa J region
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of RBPJ protein [PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; Cycloheximide inhibits the reaction [Ammonium Chloride results in increased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]
|
CTD |
PMID:22302987 |
|
NCBI chr14:61,551,366...61,736,220
Ensembl chr14:61,551,366...61,736,307
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions affects localization
|
ISO
|
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein] Cycloheximide affects the localization of RELA protein
|
CTD |
PMID:16637064 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
Ren
|
renin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased secretion of REN protein]
|
CTD |
PMID:9203624 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
| G
|
Ret
|
ret proto-oncogene
|
decreases expression
|
EXP
|
Cycloheximide results in decreased expression of RET protein
|
CTD |
PMID:17555550 |
|
NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556
|
|
| G
|
Rgn
|
regucalcin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA]
|
CTD |
PMID:18327666 |
|
NCBI chr X:4,172,537...4,190,112
Ensembl chr X:4,172,537...4,190,251
|
|
| G
|
Rhob
|
ras homolog family member B
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [cytotoxic necrotizing factor type 1 results in increased expression of RHOB protein]
|
CTD |
PMID:23732113 |
|
NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772
|
|
| G
|
Rhoc
|
ras homolog family member C
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of RHOC protein RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein]
|
CTD |
PMID:34873829 |
|
NCBI chr 2:194,975,586...194,981,637
Ensembl chr 2:194,975,242...194,983,745
|
|
| G
|
Rictor
|
RPTOR independent companion of MTOR, complex 2
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] Cycloheximide inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA]
|
CTD |
PMID:25897075 PMID:29576526 |
|
NCBI chr 2:57,539,279...57,631,291
Ensembl chr 2:57,539,311...57,631,288
|
|
| G
|
Rnf168
|
ring finger protein 168
|
multiple interactions
|
ISO
|
RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein]
|
CTD |
PMID:34873829 |
|
NCBI chr11:81,991,352...82,013,306
Ensembl chr11:81,991,360...82,013,306
|
|
| G
|
Rnf4
|
ring finger protein 4
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of RNF4 protein Cycloheximide inhibits the reaction [TAK-243 affects the localization of RNF4 protein]
|
CTD |
PMID:20943951 PMID:31285264 |
|
NCBI chr14:80,625,864...80,647,138
Ensembl chr14:80,625,866...80,647,148
|
|
| G
|
Rps27l
|
ribosomal protein S27-like
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RPS27L mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 8:76,443,658...76,448,593
Ensembl chr12:33,713,661...33,714,130 Ensembl chr 8:33,713,661...33,714,130
|
|
| G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]
|
CTD |
PMID:22689575 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238
|
|
| G
|
Rrm2
|
ribonucleotide reductase regulatory subunit M2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]
|
CTD |
PMID:22403396 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370
|
|
| G
|
Runx2
|
RUNX family transcription factor 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]
|
CTD |
PMID:15962303 PMID:18327666 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
| G
|
S100a4
|
S100 calcium-binding protein A4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A4 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837
|
|
| G
|
S100b
|
S100 calcium binding protein B
|
decreases expression
|
EXP
|
Cycloheximide results in decreased expression of S100B mRNA
|
CTD |
PMID:19146868 |
|
NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081
|
|
| G
|
Sat1
|
spermidine/spermine N1-acetyl transferase 1
|
multiple interactions
|
ISO
|
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]
|
CTD |
PMID:16637064 |
|
NCBI chr X:44,008,089...44,011,376
Ensembl chr X:44,006,781...44,011,374
|
|
| G
|
Scd
|
stearoyl-CoA desaturase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of SCD1 mRNA]
|
CTD |
PMID:8790349 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785
|
|
| G
|
Sec11c
|
SEC11 homolog C, signal peptidase complex subunit
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of SEC11C mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr18:61,590,905...61,607,247
Ensembl chr18:61,590,885...61,607,348
|
|
| G
|
Serpinb9
|
serpin family B member 9
|
multiple interactions
|
ISO
|
Cycloheximide promotes the reaction [moxestrol results in increased expression of SERPINB9 mRNA]
|
CTD |
PMID:10681578 |
|
NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974
|
|
| G
|
Serpine1
|
serpin family E member 1
|
multiple interactions
|
ISO EXP
|
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA]
|
CTD |
PMID:9798919 PMID:11007951 PMID:12111005 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357
|
|
| G
|
Serpine2
|
serpin family E member 2
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of SERPINE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERPINE2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202
|
|
| G
|
Sertad2
|
SERTA domain containing 2
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of SERTAD2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERTAD2 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr14:98,935,428...99,039,536
Ensembl chr14:98,934,769...99,041,468
|
|
| G
|
Sesn2
|
sestrin 2
|
multiple interactions decreases expression
|
ISO
|
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of SESN2 protein]
|
CTD |
PMID:25637945 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255
|
|
| G
|
Sgk1
|
serum/glucocorticoid regulated kinase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of SGK1 protein]
|
CTD |
PMID:25128767 |
|
NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231
|
|
| G
|
Sirpa
|
signal-regulatory protein alpha
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SIRPA mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 3:137,272,932...137,311,279
Ensembl chr 3:137,273,042...137,311,279
|
|
| G
|
Sirt1
|
sirtuin 1
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide promotes the reaction [antimony trichloride results in decreased expression of SIRT1 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]
|
CTD |
PMID:30055241 PMID:31082419 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
| G
|
Skic3
|
SKI3 subunit of superkiller complex
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNFRSF10B mRNA]
|
CTD |
PMID:27484784 |
|
NCBI chr 2:7,363,417...7,526,351
Ensembl chr 2:7,363,535...7,483,496
|
|
| G
|
Sla
|
src-like adaptor
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLA mRNA]
|
CTD |
PMID:9020066 |
|
NCBI chr 7:100,423,467...100,473,840
Ensembl chr 7:100,424,169...100,473,684
|
|
| G
|
Slc16a1
|
solute carrier family 16 member 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC16A1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:194,812,502...194,832,977
|
|
| G
|
Slc1a1
|
solute carrier family 1 member 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLC1A1 mRNA]
|
CTD |
PMID:19450544 |
|
NCBI chr 1:235,963,455...236,043,572
Ensembl chr 1:235,963,437...236,045,469
|
|
| G
|
Slc22a4
|
solute carrier family 22 member 4
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of SLC22A4 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC22A4 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr10:38,634,098...38,687,409
Ensembl chr10:38,634,098...38,679,920
|
|
| G
|
Slc25a27
|
solute carrier family 25, member 27
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of SLC25A27 mRNA
|
CTD |
PMID:20385226 |
|
NCBI chr 9:24,804,183...24,831,219
Ensembl chr 9:24,804,185...24,831,217
|
|
| G
|
Slc2a1
|
solute carrier family 2 member 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC2A1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742
|
|
| G
|
Slc2a4
|
solute carrier family 2 member 4
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [4-hydroxyisoleucine results in increased localization of SLC2A4 protein]
|
CTD |
PMID:22610671 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
| G
|
Slc2a5
|
solute carrier family 2 member 5
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Fructose promotes the reaction [SLC2A5 protein results in increased uptake of Fructose]]
|
CTD |
PMID:11123204 |
|
NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:165,866,172...165,894,038
|
|
| G
|
Slc39a4
|
solute carrier family 39 member 4
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Zinc deficiency results in increased expression of SLC39A4 mRNA]; Cycloheximide inhibits the reaction [Zinc results in decreased expression of SLC39A4 mRNA]
|
CTD |
PMID:18020946 |
|
NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:110,214,017...110,218,202
|
|
| G
|
Slc3a2
|
solute carrier family 3 member 2
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of SLC3A2 mRNA
|
CTD |
PMID:26621329 |
|
NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064
|
|
| G
|
Slc5a5
|
solute carrier family 5 member 5
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of SLC5A5 mRNA
|
CTD |
PMID:17164311 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691
|
|
| G
|
Slc7a5
|
solute carrier family 7 member 5
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC7A5 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412
|
|
| G
|
Smn1
|
survival of motor neuron 1, telomeric
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Paraquat results in increased expression of SMN1 mRNA alternative form]
|
CTD |
PMID:17064354 |
|
NCBI chr 2:33,224,115...33,235,162
Ensembl chr 2:33,224,095...33,235,162
|
|
| G
|
Snw1
|
SNW domain containing 1
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SNW1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 6:112,826,374...112,850,459
Ensembl chr 6:112,826,381...112,858,180
|
|
| G
|
Socs1
|
suppressor of cytokine signaling 1
|
multiple interactions increases expression
|
ISO
|
[afimoxifene co-treated with Cycloheximide] results in increased expression of SOCS1 mRNA Cycloheximide results in increased expression of SOCS1 mRNA
|
CTD |
PMID:16849584 PMID:23237828 |
|
NCBI chr10:5,389,574...5,391,265
Ensembl chr10:5,389,334...5,391,847
|
|
| G
|
Socs2
|
suppressor of cytokine signaling 2
|
multiple interactions increases expression
|
ISO
|
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS2 mRNA] Cycloheximide results in increased expression of SOCS2 mRNA
|
CTD |
PMID:15371557 PMID:23237828 |
|
NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423
|
|
| G
|
Socs3
|
suppressor of cytokine signaling 3
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of SOCS3 mRNA Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]; U 0126 inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]
|
CTD |
PMID:23237828 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
| G
|
Socs4
|
suppressor of cytokine signaling 4
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of SOCS4 mRNA
|
CTD |
PMID:23237828 |
|
NCBI chr15:23,003,130...23,017,615
Ensembl chr15:23,002,883...23,022,499
|
|
| G
|
Socs5
|
suppressor of cytokine signaling 5
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of SOCS5 mRNA
|
CTD |
PMID:23237828 |
|
NCBI chr 6:13,235,157...13,266,161
Ensembl chr 6:13,234,062...13,273,883
|
|
| G
|
Socs6
|
suppressor of cytokine signaling 6
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of SOCS6 mRNA
|
CTD |
PMID:23237828 |
|
NCBI chr18:84,386,587...84,413,927
Ensembl chr18:84,384,573...84,414,053
|
|
| G
|
Socs7
|
suppressor of cytokine signaling 7
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of SOCS7 mRNA
|
CTD |
PMID:23237828 |
|
NCBI chr10:82,848,525...82,885,201
Ensembl chr10:82,848,612...82,885,201
|
|
| G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions increases expression
|
ISO
|
Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]; Cycloheximide inhibits the reaction [polysaccharide-K results in increased expression of SOD2] Cycloheximide promotes the reaction [Paclitaxel results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vincristine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased expression of SOD2 mRNA]
|
CTD |
PMID:8037686 PMID:9852137 PMID:11154046 PMID:15330761 PMID:20495008 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
| G
|
Sort1
|
sortilin 1
|
multiple interactions increases degradation
|
EXP ISO
|
SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]; Docosahexaenoic Acids inhibits the reaction [Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]] Cycloheximide results in increased degradation of SORT1 protein mutant form
|
CTD |
PMID:22555848 PMID:24986865 PMID:25805502 |
|
NCBI chr 2:198,609,466...198,690,481
Ensembl chr 2:198,612,148...198,690,481
|
|
| G
|
Sos1
|
SOS Ras/Rac guanine nucleotide exchange factor 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOS1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:20,286,117...20,363,350
|
|
| G
|
Sptan1
|
spectrin, alpha, non-erythrocytic 1
|
multiple interactions
|
ISO
|
[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]
|
CTD |
PMID:18182247 |
|
NCBI chr 3:33,639,020...33,703,890
Ensembl chr 3:33,607,210...33,703,889
|
|
| G
|
Sqstm1
|
sequestosome 1
|
multiple interactions decreases expression
|
ISO
|
[sodium arsenite results in increased abundance of arsenite] inhibits the reaction [Cycloheximide results in decreased expression of SQSTM1 protein]; Cycloheximide promotes the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]
|
CTD |
PMID:31781319 PMID:34405320 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
| G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
increases localization
|
EXP
|
Cycloheximide results in increased localization of SRC protein
|
CTD |
PMID:10401681 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
| G
|
Srr
|
serine racemase
|
multiple interactions
|
ISO EXP
|
Cycloheximide inhibits the reaction [methyllycaconitine results in increased expression of SRR protein]
|
CTD |
PMID:24012499 |
|
NCBI chr10:60,267,936...60,285,094
Ensembl chr10:60,268,859...60,285,100
|
|
| G
|
Ssbp1
|
single stranded DNA binding protein 1
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of SSBP1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SSBP1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:70,232,740...70,242,824
Ensembl chr 4:70,232,794...70,243,700
|
|
| G
|
St18
|
ST18 C2H2C-type zinc finger transcription factor
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of ST18 mRNA
|
CTD |
PMID:23236509 |
|
NCBI chr 5:17,369,383...17,701,094
Ensembl chr 5:17,371,000...17,458,676
|
|
| G
|
St8sia1
|
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1
|
multiple interactions increases expression
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ST8SIA1 mRNA Cycloheximide results in increased expression of ST8SIA1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:177,513,966...177,651,553
Ensembl chr 4:177,520,926...177,651,553
|
|
| G
|
Stk3
|
serine/threonine kinase 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STK3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 7:67,938,341...68,208,472
Ensembl chr 7:67,938,378...68,208,508
|
|
| G
|
Stx2
|
syntaxin 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STX2 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr12:33,315,447...33,350,788
Ensembl chr12:33,315,750...33,350,788
|
|
| G
|
Sult1a1
|
sulfotransferase family 1A member 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 mRNA]
|
CTD |
PMID:16308312 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131
|
|
| G
|
Sult2b1
|
sulfotransferase family 2B member 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SULT2B1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 1:105,336,614...105,397,744
Ensembl chr 1:105,336,614...105,397,744
|
|
| G
|
Supt4h1
|
SPT4 homolog, DSIF elongation factor subunit
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SUPT4H1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr10:73,036,560...73,042,821
Ensembl chr10:73,036,343...73,043,088
|
|
| G
|
Synpo
|
synaptopodin
|
multiple interactions increases expression
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SYNPO mRNA Cycloheximide results in increased expression of SYNPO mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr18:56,326,369...56,347,359
Ensembl chr18:56,319,571...56,353,306
|
|
| G
|
Tac1
|
tachykinin, precursor 1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein]
|
CTD |
PMID:16696851 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546
|
|
| G
|
Tacc1
|
transforming, acidic coiled-coil containing protein 1
|
multiple interactions increases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in decreased expression of TACC1 mRNA Cycloheximide results in increased expression of TACC1 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr16:73,515,016...73,598,395
Ensembl chr16:73,514,889...73,598,394
|
|
| G
|
Tardbp
|
TAR DNA binding protein
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein]
|
CTD |
PMID:24477737 |
|
NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:164,334,924...164,345,204
|
|
| G
|
Tas2r106
|
taste receptor, type 2, member 106
|
multiple interactions
|
ISO
|
TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]; TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:15087236 |
|
NCBI chr 4:167,044,628...167,045,551
Ensembl chr 4:167,044,628...167,045,551
|
|
| G
|
Tbx3
|
T-box transcription factor 3
|
increases expression
|
ISO
|
cycloheximide co-treated with all-trans-retinoic acid increases expression of TBX3 mRNA in melanoma cells
|
RGD |
PMID:22535523 |
RGD:151361117 |
NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171
|
|
| G
|
Testin
|
testin gene
|
multiple interactions decreases expression decreases secretion
|
EXP
|
Cycloheximide inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Cycloheximide inhibits the reaction [lonidamine results in increased secretion of TESTIN protein] Cycloheximide results in decreased expression of TESTIN mRNA Cycloheximide results in decreased secretion of TESTIN protein
|
CTD |
PMID:11090432 |
|
NCBI chr17:3,829,012...3,864,995
Ensembl chr17:3,852,404...3,864,993
|
|
| G
|
Tfap2a
|
transcription factor AP-2 alpha
|
decreases stability multiple interactions
|
ISO
|
Cycloheximide results in decreased stability of TFAP2A protein LINC-ROR promotes the reaction [Cycloheximide results in decreased stability of TFAP2A protein]
|
CTD |
PMID:36576707 |
|
NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219
|
|
| G
|
Tff1
|
trefoil factor 1
|
multiple interactions increases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in increased expression of TFF1 mRNA; Cycloheximide inhibits the reaction [bisphenol A results in increased expression of TFF1 mRNA] Cycloheximide results in increased expression of TFF1 mRNA
|
CTD |
PMID:15072547 PMID:20875696 |
|
NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956
|
|
| G
|
Tgfa
|
transforming growth factor alpha
|
increases expression
|
ISO
|
Cycloheximide results in increased expression of TGFA mRNA
|
CTD |
PMID:15228094 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339
|
|
| G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions decreases activity
|
EXP ISO
|
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] Cycloheximide results in decreased activity of TGFB1 protein
|
CTD |
PMID:9145908 PMID:9790906 PMID:9798919 PMID:21303922 PMID:31652400 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
| G
|
Tgfbr2
|
transforming growth factor, beta receptor 2
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [tolfenamic acid results in decreased expression of TGFBR2 protein]
|
CTD |
PMID:31381904 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469
|
|
| G
|
Thbd
|
thrombomodulin
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THBD mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:156,306,632...156,320,582
|
|
| G
|
Thbs1
|
thrombospondin 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Testosterone results in decreased expression of THBS1 mRNA]
|
CTD |
PMID:16723184 |
|
NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402
|
|
| G
|
Thy1
|
Thy-1 cell surface antigen
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THY1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:53,286,148...53,291,540
|
|
| G
|
Tia1
|
TIA1 cytotoxic granule-associated RNA binding protein
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [sodium arsenite affects the localization of TIA1 protein]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]
|
CTD |
PMID:19171178 PMID:22555848 |
|
NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:120,410,251...120,440,665
|
|
| G
|
Timm17a
|
translocase of inner mitochondrial membrane 17A
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide results in decreased expression of and results in increased degradation of TIMM17A protein; YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein] Cycloheximide results in decreased expression of TIMM17A protein
|
CTD |
PMID:24315374 |
|
NCBI chr13:49,282,918...49,296,363
Ensembl chr13:49,282,918...49,307,904
|
|
| G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
decreases response to substance
|
EXP
|
TIMP1 protein results in decreased susceptibility to Cycloheximide
|
CTD |
PMID:15860571 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
| G
|
Tiparp
|
TCDD-inducible poly(ADP-ribose) polymerase
|
multiple interactions increases expression
|
ISO
|
AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]
|
CTD |
PMID:12147270 |
|
NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:152,063,751...152,090,406
|
|
| G
|
Tjp1
|
tight junction protein 1
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] Cycloheximide results in decreased expression of TJP1 protein
|
CTD |
PMID:16087364 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
|
|
| G
|
Tm7sf3
|
transmembrane 7 superfamily member 3
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TM7SF3 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 4:181,248,819...181,280,844
Ensembl chr 4:181,248,822...181,280,844
|
|
| G
|
Tmem263
|
transmembrane protein 263
|
increases expression multiple interactions
|
ISO
|
Cycloheximide results in increased expression of TMEM263 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TMEM263 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 7:20,497,852...20,516,011
Ensembl chr 7:20,497,852...20,516,428
|
|
| G
|
Tnf
|
tumor necrosis factor
|
increases response to substance multiple interactions
|
ISO EXP
|
TNF protein results in increased susceptibility to Cycloheximide [TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; Cycloheximide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Cycloheximide promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] Cycloheximide inhibits the reaction [TNF protein results in decreased export of Potassium]; Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] [Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of TNF protein]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; Cycloheximide inhibits the reaction [Zinc deficiency promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA]
|
CTD |
PMID:8037686 PMID:8071060 PMID:12185005 PMID:12812920 PMID:12925536 PMID:15701621 PMID:16077199 PMID:17337591 PMID:18182247 PMID:21146893 PMID:22121136 PMID:22241084 PMID:22258905 PMID:22319556 PMID:22555848 PMID:24068670 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfaip1
|
TNF alpha induced protein 1
|
multiple interactions
|
ISO
|
TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]
|
CTD |
PMID:37302538 |
|
NCBI chr10:63,915,824...63,930,514
Ensembl chr10:63,915,825...63,930,514
|
|
| G
|
Tnfaip3
|
TNF alpha induced protein 3
|
multiple interactions
|
ISO
|
[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA]
|
CTD |
PMID:21146893 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979
|
|
| G
|
Tnfrsf10b
|
TNF receptor superfamily member 10b
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Docetaxel results in increased expression of TNFRSF10A protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein]
|
CTD |
PMID:11212279 |
|
NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082
|
|
| G
|
Tnfrsf11b
|
TNF receptor superfamily member 11B
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of TNFRSF11B mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075
|
|
| G
|
Tnfrsf8
|
TNF receptor superfamily member 8
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNFRSF8 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 5:162,406,387...162,451,620
Ensembl chr 5:162,406,387...162,451,620
|
|
| G
|
Tnfsf10
|
TNF superfamily member 10
|
multiple interactions
|
ISO
|
[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide]; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF10 mRNA]
|
CTD |
PMID:11007951 PMID:18222423 PMID:22343715 |
|
NCBI chr 2:112,136,550...112,155,903
|
|
| G
|
Tnfsf11
|
TNF superfamily member 11
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF11 mRNA] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA]
|
CTD |
PMID:11007951 PMID:17295206 PMID:18327666 PMID:18636177 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
| G
|
Tnnc1
|
troponin C1, slow skeletal and cardiac type
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNNC1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr16:6,408,607...6,412,070
Ensembl chr16:6,408,607...6,412,070
|
|
| G
|
Tp53
|
tumor protein p53
|
increases response to substance multiple interactions decreases expression increases degradation
|
ISO EXP
|
TP53 mutant form results in increased susceptibility to Cycloheximide Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein]; Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein]; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of TRP53 protein] Cycloheximide results in decreased expression of TP53 protein
|
CTD |
PMID:9790906 PMID:10760090 PMID:15016801 PMID:20943951 PMID:21875941 PMID:27993609 PMID:31645432 PMID:35821281 More...
|
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
| G
|
Tp53i11
|
tumor protein p53 inducible protein 11
|
multiple interactions decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of TP53I11 mRNA] Cycloheximide results in decreased expression of TP53I11 mRNA
|
CTD |
PMID:19333544 |
|
NCBI chr 3:99,600,213...99,615,462
Ensembl chr 3:99,600,159...99,615,432
|
|
| G
|
Tp63
|
tumor protein p63
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [trichostatin A results in increased expression of TP63 protein alternative form]
|
CTD |
PMID:20043870 |
|
NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177
|
|
| G
|
Trpv4
|
transient receptor potential cation channel, subfamily V, member 4
|
increases degradation multiple interactions
|
ISO
|
Cycloheximide results in increased degradation of TRPV4 protein tanshinone inhibits the reaction [Cycloheximide results in increased degradation of TRPV4 protein]
|
CTD |
PMID:39089414 |
|
NCBI chr12:47,599,161...47,638,143
Ensembl chr12:47,599,035...47,638,143
|
|
| G
|
Tubgcp3
|
tubulin gamma complex component 3
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TUBGCP3 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr16:83,553,950...83,614,626
Ensembl chr16:83,553,959...83,614,623
|
|
| G
|
Txnrd1
|
thioredoxin reductase 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Acrolein results in increased expression of TXNRD1 mRNA]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA]
|
CTD |
PMID:12663510 PMID:15652504 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
| G
|
Tymp
|
thymidine phosphorylase
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of TYMP protein salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]]
|
CTD |
PMID:30796972 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003
|
|
| G
|
Tyms
|
thymidylate synthetase
|
multiple interactions decreases expression
|
ISO
|
cinobufagin promotes the reaction [Cycloheximide results in decreased expression of TYMS protein]; Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA]
|
CTD |
PMID:17172411 PMID:35427566 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097
|
|
| G
|
Tyr
|
tyrosinase
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Quercetin results in increased activity of TYR protein] [resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein; SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein]
|
CTD |
PMID:14717847 PMID:29621941 |
|
NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857
|
|
| G
|
Uchl1
|
ubiquitin C-terminal hydrolase L1
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Mevinphos results in increased expression of UCHL1 protein]
|
CTD |
PMID:15545831 |
|
NCBI chr14:41,838,859...41,849,743
Ensembl chr14:41,838,861...41,849,417
|
|
| G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
multiple interactions decreases expression
|
ISO
|
[Cycloheximide co-treated with Estradiol] results in decreased expression of UGT1A1 mRNA Cycloheximide results in decreased expression of UGT1A1 mRNA
|
CTD |
PMID:15072547 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
| G
|
Ugt1a6a
|
UDP glucuronosyltransferase family 1 member A6a
|
multiple interactions
|
EXP
|
Cycloheximide inhibits the reaction [Paraquat results in increased expression of UGT1A6 mRNA]
|
CTD |
PMID:22846377 |
|
NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
| G
|
Ulk1
|
unc-51 like autophagy activating kinase 1
|
decreases expression multiple interactions
|
ISO
|
Cycloheximide results in decreased expression of ULK1 protein Antimycin A inhibits the reaction [Cycloheximide results in decreased expression of ULK1 protein]; Cycloheximide inhibits the reaction [Antimycin A results in increased expression of ULK1 protein]
|
CTD |
PMID:27629431 |
|
NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746
|
|
| G
|
Usp7
|
ubiquitin specific peptidase 7
|
multiple interactions
|
ISO
|
USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein]
|
CTD |
PMID:35821281 |
|
NCBI chr10:7,335,508...7,432,018
Ensembl chr10:7,367,604...7,432,013
|
|
| G
|
Vasp
|
vasodilator-stimulated phosphoprotein
|
multiple interactions
|
ISO
|
VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]
|
CTD |
PMID:18182247 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650
|
|
| G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]
|
CTD |
PMID:12892526 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
| G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions increases expression
|
EXP ISO
|
Cycloheximide promotes the reaction [Estradiol results in increased expression of VEGFA mRNA alternative form] [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA Cycloheximide results in increased expression of VEGFA mRNA Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]
|
CTD |
PMID:8344219 PMID:8537383 PMID:10788502 PMID:11641398 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
| G
|
Vegfd
|
vascular endothelial growth factor D
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VEGFD mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr X:33,704,582...33,740,305
Ensembl chr X:33,706,055...33,740,167
|
|
| G
|
Virma
|
vir like m6A methyltransferase associated
|
affects response to substance
|
ISO
|
VIRMA gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr 5:29,758,529...29,822,030
Ensembl chr 5:29,758,147...29,822,156
|
|
| G
|
Vldlr
|
very low density lipoprotein receptor
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VLDLR mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:234,240,121...234,272,154
|
|
| G
|
Vsnl1
|
visinin-like 1
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VSNL1 mRNA]
|
CTD |
PMID:11007951 |
|
NCBI chr 6:39,757,721...39,878,556
Ensembl chr 6:39,757,722...39,878,556
|
|
| G
|
Wwox
|
WW domain-containing oxidoreductase
|
affects response to substance
|
ISO
|
WWOX gene SNP affects the susceptibility to Cycloheximide
|
CTD |
PMID:25622337 |
|
NCBI chr19:59,338,402...60,269,323
Ensembl chr19:59,341,233...60,269,441
|
|
| G
|
Xiap
|
X-linked inhibitor of apoptosis
|
multiple interactions
|
ISO
|
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA]
|
CTD |
PMID:29576526 |
|
NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978
|
|
| G
|
Yap1
|
Yes1 associated transcriptional regulator
|
multiple interactions
|
ISO
|
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of YAP1 mRNA
|
CTD |
PMID:19684285 |
|
NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:13,380,551...13,451,437
|
|
| G
|
Yme1l1
|
YME1-like 1 ATPase
|
multiple interactions
|
ISO
|
YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein]
|
CTD |
PMID:24315374 |
|
NCBI chr17:90,195,485...90,235,675
Ensembl chr17:90,195,584...90,356,331
|
|
|
|
| G
|
Hoxb9
|
homeo box B9
|
multiple interactions
|
ISO
|
[Penicillins co-treated with Streptomycin] results in increased expression of HOXB9 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872
|
|
| G
|
Pax3
|
paired box 3
|
multiple interactions
|
ISO
|
[Penicillins co-treated with Streptomycin] results in increased expression of PAX3 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141
|
|
| G
|
Tcf15
|
transcription factor 15
|
multiple interactions
|
ISO
|
[Penicillins co-treated with Streptomycin] results in increased expression of TCF15 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 3:161,099,301...161,105,083
Ensembl chr 3:161,099,301...161,105,083
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
Streptomycin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
|
CTD |
PMID:17699551 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Uncx
|
UNC homeobox
|
multiple interactions
|
ISO
|
[Penicillins co-treated with Streptomycin] results in increased expression of UNCX mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr12:20,206,604...20,211,125
Ensembl chr12:20,206,609...20,211,125
|
|